| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Anavex Life Sciences Corp.$2.5
-0.2 (-7.3%)
C 43Pipeline Score Overvalued Biotech · Clinical
Market Cap
258.09 M
EPS
-0.46
P/E Ratio
-5.99 $
Value Trade
2.80 M
SEC Financials
Q4 2025Dilution Risk
R&D Expenses
4.66 M
Operating CF
-7.15 M
Total Assets
132.99 M
Total Liabilities
6.37 M
Equity
126.62 M
D/E Ratio
12,345
-11.35 %
Week
-24.72 %
1 Month
-35.06 %
3 Month
-14.98 %
6 Month
-76.57 %
5 Year
-66.31 %
All Time
Cash Data
Cash Position
131.75 M
Monthly Burn
2.38 M
Runway
50.5 mo
Burn Trend
SEC Filing
Feb 9, 2026
Overview
Volume
749.69 K
52 Week Range
2.61 - 13.99
% held by Insiders
3.12 %
% held by Institutions
43.42 %
Enterprise Value
126.34 M
Total Shares
92.62 M
Short %
16.2 %
Float Shares
87.81 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Anavex Life Sciences Corp.
762Total events
2Upcoming
141Tier-1 (high impact)
2010 – 2026Coverage
Upcoming catalysts 2
Event history 760
May 20, 2026
▼Quarterly UpdateCorporate
Received Nasdaq delinquency notification for late Form 10-Q filing
May 6, 2026
●Quarterly UpdateCorporate
Company expects to file Form 12b-25 to extend Q1 2026 10-Q filing date
Apr 30, 2026
Apr 14, 2026
◆Oral PresentationPresentation
Presentation at 25th Annual Needham Virtual Healthcare Conference
Q2 2026
◆Timing GuidanceANAVEX3-71Presentation
Topline data from Phase 2 ANAVEX 3-71 trial expected in calendar Q2 2026
Alzheimer's diseasesource ↗
Q2 2026
◆Timing GuidanceblarcamesinePresentation
Topline data from Phase 2 Parkinson's disease trial expected in calendar Q2 2026
Parkinson's diseasesource ↗
Mar 30, 2026
▼CHMP Negative OpinionblarcamesineEx-US Regulatory
CHMP negative opinion led to withdrawal of EU marketing authorization application for blarcamesine in early Alzheimer's disease
early Alzheimer's diseasesource ↗
Mar 30, 2026
▼EU MAA SubmissionblarcamesineEx-US Regulatory
Withdrawal of EU marketing authorization application for blarcamesine in early Alzheimer's disease
early Alzheimer's diseasesource ↗
Mar 30, 2026
◆FDA Feedback ReceivedblarcamesineFDA Meeting
Additional data submitted to FDA to discuss potential NDA pathway for blarcamesine in early Alzheimer's disease
early Alzheimer's diseasesource ↗
Mar 30, 2026
◆Other Regulator MilestoneblarcamesineEx-US Regulatory
Regulatory engagement with EU authorities for blarcamesine in Parkinson's disease
Parkinson's diseasesource ↗
Mar 25, 2026
▼CHMP Negative OpinionblarcamesineEx-US Regulatory
CHMP indicated it would not issue a positive opinion for blarcamesine MAA
early Alzheimer's diseasesource ↗
Drug Pipeline Intelligence
C43
Pipeline Score $119M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.5x
rNPV / MCap Top 63%
Micro Cap (rank 338 of 911)
Percentile RankAnavex Life Sciences Corp. carries a moderate pipeline score (43/100), with $949M risk-adjusted pipeline value, led by High dose ANAVEX2-73 in Alzheimer Disease (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANAVEX2-73 Small molecule | Rett Syndrome | Phase 3 | NCT03758924 | 90% | $795M | COMPLETED | 64 | - | - | Oct 30, 2020 | - | Jan 12, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
blarcamesine Fast TrackOrphanRare Pediatric | early Alzheimer's disease | Phase 2b/3 | 2026-03-23 | 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI1 control group after 144 weeks (33.1 months) of treatment; R² increasing by 78% for ADAS-Cog13 (from R²=0.23 to R²=0.41) Read More | Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease Read More | |
blarcamesine Fast TrackOrphanRare Pediatric | early Alzheimer's disease | Phase 2b/3 | 2026-03-23 | 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI1 control group after 144 weeks (33.1 months) of treatment; R² increasing by 78% for ADAS-Cog13 (from R²=0.23 to R²=0.41) Read More | Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease Read More | |
blarcamesine Fast TrackOrphanRare Pediatric | early Alzheimer's disease | Phase 2b/3 | 2026-03-23 | 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI1 control group after 144 weeks (33.1 months) of treatment; R² increasing by 78% for ADAS-Cog13 (from R²=0.23 to R²=0.41) Read More | Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AVXL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AVXL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AVXLAnavex Life Sciences Receives Expected Nasdaq Delinquency Notification
Anavex Life Sciences Corp. received a delinquency notification from Nasdaq due to its failure to file Form 10-Q for the quarter ended March 31, 2026. The company has until July 20, 2026, to submit a plan to regain compliance. Despite this notification, there is no immediate impact on its stock.
Read more →AVXLAnavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer
Anavex Life Sciences Corp. has appointed Dr. Terrie Kellmeyer as Interim Chief Executive Officer following the resignation of former CEO Christopher Missling. Dr. Kellmeyer, who has nearly three decades of experience in the pharmaceutical industry, is expected to lead the company's clinical development efforts and enhance its initiatives in treating neurological disorders. The company also announced a delay in filing its Quarterly Report due to regulatory compliance issues, which it plans to address in an upcoming conference call.
Read more →AVXLAnavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease
Anavex Life Sciences has identified new scientific evidence linking autism spectrum disorder (ASD) and Alzheimer's disease (AD), highlighting common biological dysfunctions, particularly in autophagy. This research underpins the company's strategic focus on the investigational drug blarcamesine, designed to enhance autophagy, which has shown potential in clinical trials for both conditions. The findings provide a rationale for advancing blarcamesine into pivotal studies, aiming to tackle disease mechanisms that affect both neurodevelopmental and neurodegenerative disorders.
Read more →AVXLAnavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
Anavex Life Sciences Corp. will present at the 25th Annual Needham Virtual Healthcare Conference from April 13 to 16, 2026. CEO Christopher U. Missling and his team will discuss the company's advancements in treatments for neurodegenerative and neurodevelopmental disorders, including Alzheimer's and Parkinson's diseases. The presentation is scheduled for April 14 at 1:30 PM ET, with a live audio webcast available.
Read more →AVXLAnavex Life Sciences Provides Comprehensive Regulatory Update
Anavex Life Sciences has provided an update on the regulatory progress of its drug blarcamesine for early Alzheimer's disease, noting ongoing dialogue with the EMA and FDA. The company aims to address points raised during the EU regulatory review while also expanding discussions to include Parkinson's disease and rare diseases like Rett syndrome. Despite the withdrawal of its marketing authorization application in the EU, Anavex is optimistic about future regulatory pathways and continues to gather data to support its development programs.
Read more →AVXL▼ -34.6%on this newsshared move
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
Anavex Life Sciences has withdrawn its application for marketing authorization of blarcamesine in the EU for early Alzheimer's disease treatment, following negative feedback from the EMA's CHMP. Despite this setback, Anavex is committed to advancing the drug's development and addressing the concerns raised by the regulatory body. The company aims to gather more data to support future applications.
Read more →AVXL▲ +9.4%on this news· ran to -29% by day 3shared move
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
Anavex Life Sciences Corporation presented new data on its drug blarcamesine at the AD/PD 2026 Conference, highlighting its potential for preserving brain volume in early Alzheimer's disease patients. The data showed a correlation between treatment with blarcamesine and improved clinical outcomes over a long-term period compared to a control group. An emphasis was placed on the drug's oral administration and manageable side effects, which could enhance patient compliance and quality of life. The results support Anavex's precision medicine approach by showing greater benefits for genetically defined patient populations.
Read more →AVXLNew Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease
Anavex Life Sciences announced a new study linking autophagy failure to Alzheimer's disease pathology. The research suggests that impaired autophagy precedes amyloid beta and tau aggregation, highlighting the potential for early intervention. The findings support Anavex's drug candidate, blarcamesine, which aims to restore autophagy and address Alzheimer's disease mechanisms.
Read more →AVXLAnavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
Anavex Life Sciences Corp. announced positive new data on blarcamesine during the AD/PD 2026 Conference. The data reveal that blarcamesine can improve motor function and stimulate dopaminergic nerve fiber growth in a new Parkinson's disease model that combines alpha-synuclein accumulation with noradrenergic degeneration. The study presents evidence supporting blarcamesine as a candidate for disease-modifying therapy in Parkinson's disease. Anavex's CEO expressed optimism regarding the drug's potential to advance clinical programs in early-stage Parkinson's treatment.
Read more →AVXLAnavex Life Sciences to Present at the Citizens Life Sciences Conference
Anavex Life Sciences Corp. will present at the Citizens Life Sciences Conference on March 10, 2026. CEO Christopher U Missling will discuss the company's innovative treatments for CNS disorders, including Alzheimer's and Parkinson's diseases. Anavex's lead candidate, ANAVEX®2-73, has shown positive results in multiple clinical trials, indicating its potential effectiveness.
Read more →AVXLAnavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
Anavex Life Sciences Corp. will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CEO Christopher U Missling will discuss the company's innovative treatments for CNS disorders, including Alzheimer's and Parkinson's diseases. Anavex's lead drug candidate, ANAVEX®2-73, has completed multiple successful clinical trials.
Read more →AVXLAnavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors
Anavex Life Sciences Corp. has appointed Dr. Axel Paeger to its Board of Directors. Dr. Paeger, with over 30 years of healthcare leadership experience, will guide the company in advancing its mission to develop new treatments for neurological disorders. His background includes significant roles in inpatient medical care and leadership at AMEOS Group, a major healthcare provider in Europe.
Read more →AVXL▲ +6.1%on this news
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
Anavex Life Sciences Corp. reported its fiscal 2026 first quarter financial results, highlighting progress in its clinical pipeline, particularly with oral blarcamesine for early Alzheimer's disease. CEO Christopher U. Missling expressed optimism about the drug's therapeutic potential and the company's commitment to working with regulatory agencies. Anavex aims to develop targeted therapies for various CNS disorders.
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
Anavex Life Sciences Corp. will announce its fiscal 2026 first quarter financial results on February 9, 2026. The company will host a conference call at 8:30 am ET to discuss these results and recent corporate developments. Anavex is known for its innovative treatments targeting neurodegenerative and neurodevelopmental disorders.
Read more →AVXL▲ +8.2%on this news
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
Anavex Life Sciences Corp. has announced its participation in ACCESS-AD, a European initiative aimed at enhancing Alzheimer's disease care through innovative diagnostic and therapeutic methods. The program, funded by the European Commission, will evaluate blarcamesine, an investigational therapy, within a precision medicine framework. This collaboration seeks to improve patient access to effective treatments and streamline care pathways across Europe.
Read more →AVXLAnavex Life Sciences Appoints Senior Vice President Global Head of Neurology
Anavex Life Sciences has appointed Dr. Wolfgang Liedtke as Senior Vice President, Global Head of Neurology. Dr. Liedtke, a board-certified neurologist with over 25 years of experience, will leverage his expertise to enhance the company's focus on innovative treatments for CNS diseases. The appointment comes as Anavex aims to improve patient outcomes in neurodegenerative and neurodevelopmental disorders. The leadership change reflects a strategic move to advance the company’s mission in transforming brain health.
Read more →AVXLAnavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program
Anavex Life Sciences Corp. has received positive feedback from the FDA regarding its Alzheimer's disease program during a Type C meeting. The FDA expressed interest in the results of Anavex's clinical trials and discussed potential pathways to support a New Drug Application for the treatment. Anavex plans to submit additional data from its ongoing Phase IIb/III program to facilitate the evaluation process. The company remains committed to advancing innovative therapies for neurodegenerative diseases.
Read more →AVXLAnavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
Anavex Life Sciences Corp. has submitted a request to the European Medicines Agency (EMA) for a re-examination of its application regarding the drug blarcamesine, intended for the treatment of early Alzheimer's disease. This process will involve a new evaluation led by a different rapporteur and co-rapporteur and aims to address the unmet needs in Alzheimer's treatment. The company emphasizes its commitment to collaborate closely with the EMA through this re-examination procedure. Anavex seeks to advance the development of innovative oral treatments that could significantly impact Alzheimer's disease and its socio-economic burden.
Read more →AVXL▲ +11.6%on this news
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Anavex Life Sciences Corp. will present data on its drug blarcamesine at the 18th CTAD Conference in San Diego from December 1-4, 2025. The presentations will include one oral late-breaking communication and two poster presentations. Blarcamesine has shown meaningful effects in slowing cognitive decline in early Alzheimer's patients, supported by clinical data.
Read more →AVXL▲ +12.3%on this news· ran to +25% by day 1shared move
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
Anavex Life Sciences reported its fiscal 2025 fourth quarter financial results, highlighting progress in its clinical pipeline, particularly with oral blarcamesine for early Alzheimer's disease. The company plans to request a re-examination of the EMA's negative opinion on blarcamesine. Financially, Anavex has a cash runway exceeding three years despite a reported net loss.
Read more →AVXL▲ +12.3%on this news· ran to +25% by day 1shared move
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update Company to host a webcast today at 8:30 a.m. Eastern Time
Anavex Life Sciences Corp. reported its fiscal 2025 fourth quarter financial results, indicating a net loss of $9.8 million, down from $11.6 million in the previous year. The company remains focused on developing innovative treatments for neurodegenerative diseases such as Alzheimer's. Positive clinical trial results for its lead drug candidate, ANAVEX 2-73, have been noted, particularly its efficacy in early-stage Alzheimer's patients. The company will host a webcast to discuss these results and further details of its financial situation.
Read more →AVXLAnavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced its participation in the upcoming 44th Annual J.P. Morgan Healthcare Conference, where CEO Christopher U Missling will present on January 14, 2026. The conference is noted for being a significant event in the healthcare investment landscape, bringing together industry leaders and emerging companies. Anavex is recognized for its development of novel therapeutics aimed at various neurodegenerative and neurodevelopmental disorders, with a focus on Alzheimer's and Parkinson's diseases.
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025
Anavex Life Sciences Corp. (Nasdaq: AVXL) is set to report its financial results for the fiscal fourth quarter on November 25, 2025. A conference call will follow to discuss the results and recent corporate developments. Anavex is focused on advancing treatments for various neurological disorders, with notable progress in clinical trials for their lead drug candidate, ANAVEX®2-73.
Read more →AVXL▼ -35.9%on this newsshared move
Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer’s Disease
Anavex Life Sciences Corp. has provided a regulatory update on its drug blarcamesine for early Alzheimer's disease. Following a negative trend vote from the CHMP, the company plans to request a re-examination of the decision. Additionally, the FDA has encouraged Anavex to meet and discuss its clinical trial results. The company remains optimistic about advancing its investigational therapy.
Read more →AVXL▼ -35.9%on this newsshared move
Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease Company plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet
Anavex Life Sciences Corp. has provided a regulatory update on its drug blarcamesine for treating early Alzheimer's disease, indicating plans to request a re-examination after initial negative feedback from the CHMP. The FDA has encouraged the company to meet and discuss its clinical trial findings. The company aims to present additional biomarker data and continue collaborations with regulatory bodies to advance its investigational therapy. Despite the initial setback, the treatment is viewed as a promising option due to its strong safety profile and potential effectiveness.
Read more →AVXLAnavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group
Anavex Life Sciences reported positive findings from its Phase IIb/III trial of blarcamesine for early Alzheimer's disease. The treatment demonstrated significant cognitive benefits, with a notable reduction in cognitive decline compared to the Alzheimer's Disease Neuroimaging Initiative control group. Patients treated with blarcamesine experienced an estimated 77.4 weeks of 'time saved', indicating prolonged functionality. The drug also restored impaired autophagy, suggesting a promising therapeutic mechanism.
Read more →AVXLAnavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’
Anavex Life Sciences announced that Prof. Dr. Timo Grimmer presented at the 35th Alzheimer Europe Conference, discussing the oral treatment blarcamesine for Alzheimer's disease. The presentation emphasized the convenience for patients and families. Anavex's ongoing clinical trials for blarcamesine show promise in treating Alzheimer's and other CNS disorders.
Read more →AVXLAnavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program
Anavex Life Sciences has successfully developed a once-daily oral tablet formulation for its ANAVEX®3-71 program, achieving its primary endpoint in the ANAVEX3-71-002 trial. The new formulation shows improved pharmacokinetics over the immediate-release capsule, allowing for once-daily dosing. This advancement is expected to address the medical needs of patients with schizophrenia and neurodegenerative disorders.
Read more →AVXLAnavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
Anavex Life Sciences announced positive topline results from its Phase 2 study of ANAVEX®3-71 for treating schizophrenia. The study met its primary endpoint, showing safety and tolerability in adults on stable antipsychotic medication. Additionally, encouraging trends in biomarkers suggest potential disease-modifying effects, supporting further development of the drug.
Read more →AVXLAnavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease Trial
Anavex Life Sciences announced the publication of a study on oral blarcamesine, highlighting its effectiveness in improving quality of life for early Alzheimer's disease patients. The Phase IIb/III trial demonstrated significant benefits for up to 70% of participants, showcasing a novel precision medicine approach. The findings suggest blarcamesine could reshape Alzheimer's care by targeting genetically relevant populations.
Read more →AVXL▲ +9.7%on this news
Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer’s Disease Trial
Anavex Life Sciences announced promising results from its Phase IIb/III trial of blarcamesine, showing significant cognitive stabilization in early Alzheimer's disease patients. The treatment demonstrated an 84.7% reduction in cognitive decline compared to placebo over 48 weeks. This novel approach could benefit a large portion of early-stage Alzheimer's patients, marking a significant advancement in personalized medicine for the condition.
Read more →AVXLAnavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025
Anavex Life Sciences Corp. will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Christopher U. Missling will speak on September 9, 2025, at 1:00 p.m. ET. The company focuses on developing treatments for Alzheimer's, Parkinson's, and other CNS disorders, with promising results from clinical trials.
Read more →AVXLAnavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine
Anavex Life Sciences has published a peer-reviewed study in iScience detailing the autophagy mechanism activated by blarcamesine through sigma-1 receptor (S1R) interaction. This study confirms that blarcamesine enhances autophagic flux and proteostasis, potentially addressing neurodegenerative diseases like Alzheimer's. The findings may provide insights into the biochemical processes underlying autophagy modulation.
Read more →AVXLAnavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease
Anavex Life Sciences announced a peer-reviewed publication demonstrating that blarcamesine effectively prevents cognitive impairment and oxidative injury in an Alzheimer's disease model. The study highlights the drug's potential as a preventative treatment for Alzheimer's, showing significant protection against amyloid toxicity. The findings support further clinical trials aimed at establishing blarcamesine's efficacy in humans.
Read more →AVXL▼ -5%on this news
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
Anavex Life Sciences Corp. reported its financial results for the third quarter of fiscal 2025, highlighting advancements in its Alzheimer's disease treatment. The company showcased positive data for its lead drug candidate, blarcamesine, during the AAIC 2025 conference. Anavex continues to focus on developing innovative therapies for various CNS disorders.
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025
Anavex Life Sciences Corp. is set to announce its financial results for the third quarter of fiscal 2025 on August 12, 2025. Following the results announcement, management will conduct a conference call to discuss their financial outcomes and growth strategies. The company's lead candidate, ANAVEX®2-73, has shown success in several clinical trials aimed at treating neurodegenerative diseases.
Read more →AVXLAnavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
Anavex Life Sciences announced positive results from its Phase IIb/III trial of blarcamesine for early Alzheimer's disease, highlighting significant benefits in cognition and function over nearly four years of treatment. Data presented at the Alzheimer's Association International Conference indicate that earlier treatment initiation yields better results, with marked improvements noted in clinical trial endpoints. The drug showed a favorable safety profile, although some treatment-related adverse events were reported. Anavex continues to advocate for its precision medicine approach to enhance treatment efficacy and accessibility.
Read more →AVXL▲ +7.2%on this news
ANAVEX SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Long-Term Investors to Contact the Firm
Kaskela Law LLC is conducting an investigation into Anavex Life Sciences Corp. concerning potential breach of fiduciary duty claims on behalf of long-term shareholders. The firm highlights a securities fraud complaint filed due to alleged misleading statements by Anavex related to its product blarcamesine and its research outcomes. Following the announcement of disappointing results from the Excellence study, Anavex's stock suffered a significant decline in value. The investigation aims to determine if board members violated securities laws or their fiduciary duties.
Read more →AVXLAnavex Life Sciences to Participate at Upcoming Healthcare Conferences
Anavex Life Sciences Corp. has announced that its CEO, Dr. Christopher U. Missling, will participate in two upcoming healthcare conferences: the H.C. Wainwright 3rd Annual BioConnect Investor Conference and the H.C. Wainwright 6th Annual Neuro Perspectives Conference, both in New York City. The company is focused on developing innovative therapies for various CNS disorders, with its lead drug candidate, ANAVEX®2-73, already showing promising results in several clinical trials. These appearances at key conferences signify Anavex's ongoing commitment to advancing its therapeutic developments and engaging with investors.
Read more →AVXL▼ -5%on this newsshared move
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
Anavex Life Sciences Corp. reported its fiscal 2025 second quarter financial results, highlighting continued advancements in its Alzheimer's disease and schizophrenia treatments. The company successfully enrolled participants in its Phase 2 study of ANAVEX®3-71 for schizophrenia, expecting to share top-line data later this year. Notably, the latest data on blarcamesine demonstrated sustained benefits for early Alzheimer's patients. Financially, despite a slight increase in net loss, the company maintains a solid cash runway for further development.
Read more →AVXL▼ -7.6%on this news
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
Anavex Life Sciences Corp. will release its financial results for the second quarter of fiscal 2025 on May 13, 2025. The company will host a conference call on the same day to discuss these results and provide an update on its growth strategy. Anavex is known for developing novel therapies targeting various neurodegenerative and psychiatric disorders. Their lead candidate, ANAVEX®2-73, has shown promise in clinical trials for Alzheimer's disease and other CNS conditions.
Read more →AVXLAnavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
Anavex Life Sciences has announced the full enrollment of 71 participants in its Phase 2 study of ANAVEX®3-71 for schizophrenia treatment. The study aims to evaluate the drug's efficacy and safety, with preliminary results indicating promising safety and EEG biomarker data. The company expects to report top-line data in the second half of 2025.
Read more →AVXLAnavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX 3-71 for the Treatment of Schizophrenia
Anavex Life Sciences has announced the full enrollment of 71 participants in its Phase 2 clinical study of ANAVEX®3-71, targeting schizophrenia. The study comprises two parts, with Part A focusing on multiple ascending doses and reporting encouraging preliminary safety results. The larger Part B aims to gather comprehensive clinical and biomarker data regarding the drug's efficacy and safety. Results from this study are anticipated in the latter half of 2025, addressing a significant unmet medical need in schizophrenia treatment.
Read more →AVXLAnavex Life Sciences to Participate in The Citizens Life Sciences Conference
Anavex Life Sciences Corp. is participating in The Citizens Life Sciences Conference scheduled for May 7-8, 2025, in New York. The CEO, Christopher U Missling, PhD, will present at 3:30 PM (ET) on May 7. The company focuses on developing treatments for various CNS disorders, with its lead candidate ANAVEX®2-73 having completed several successful clinical trials for Alzheimer's disease and Parkinson's disease. Additionally, ANAVEX®3-71 shows promising results in preclinical models for Alzheimer's disease-related pathologies.
Read more →AVXLAnavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board
Anavex Life Sciences Corp. has appointed Professor Dr. Audrey Gabelle, an expert in Alzheimer's disease and digital health, to its Scientific Advisory Board. Dr. Gabelle has over a decade of experience in clinical trials and a strong publication record, which could benefit Anavex's mission to develop treatments for neurodegenerative disorders. She expressed enthusiasm for the role and for contributing to the development of blarcamesine, Anavex's lead drug candidate targeting Alzheimer's disease.
Read more →AVXLAnavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East
Anavex Life Sciences Corp. announced that Dr. Marwan Noel Sabbagh presented at the 9th International Conference on Alzheimer's Disease and Related Disorders held in Abu Dhabi. The presentation highlighted the investigational agent blarcamesine, focusing on its novel mechanism for treating Alzheimer's disease through autophagy restoration via SIGMAR1 activation. The conference brought together various healthcare professionals and researchers interested in Alzheimer's and related disorders in the MENA region. This event underscores Anavex's commitment to addressing significant healthcare challenges in neurodegenerative diseases.
Read more →AVXLAnavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
Anavex Life Sciences announced the positive results of its ATTENTION-AD trial, which showed that over four years of treatment with blarcamesine significantly improved clinical outcomes in patients with early Alzheimer's disease. The trial indicated that early and continuous treatment leads to better cognitive stability, with no significant safety concerns reported. The data suggests that establishing a routine treatment protocol could enhance long-term patient quality of life. Continued research and development for blarcamesine will support future Phase III and IV studies aimed at broader patient access and enhanced efficacy.
Read more →AVXLAnavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
Anavex Life Sciences Corp. will present at the 24th Annual Needham Virtual Healthcare Conference from April 7-10, 2025. Christopher U Missling, PhD, President & CEO, is scheduled to speak on April 7 at 3:45 PM ET. Anavex is focused on developing innovative treatments for a range of CNS disorders, including Alzheimer's and Parkinson's diseases, and has seen success in multiple clinical trials. A live audio webcast of the presentation will be available on the company's website.
Read more →AVXLAnavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference
Anavex Life Sciences Corp. announced its participation in the 45th Annual TD Cowen Health Care Conference, where CEO Christopher U Missling will present on March 3, 2025. The company is involved in developing treatments for Alzheimer's disease and other CNS disorders. Anavex's lead candidate, ANAVEX®2-73, has shown potential in clinical trials, emphasizing its commitment to addressing neurodegenerative diseases. The conference represents an opportunity for Anavex to enhance its visibility and discuss its innovative therapeutics.
Read more →AVXLAnavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update
Anavex Life Sciences Corp. reported its financial results for the first quarter of fiscal 2025, highlighting a net loss of $12.1 million. The company announced positive stakeholder support for its oral Alzheimer's treatment and disclosed recent patent filings for novel formulations. Significant clinical trial results showed that blarcamesine significantly slowed the progression of early Alzheimer's disease. However, operating expenses and net losses have increased compared to the previous year, raising concerns about financial health moving forward.
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025
Anavex Life Sciences Corp. has announced it will release its financial results for the first quarter of fiscal 2025 on February 12, 2025. A conference call will follow, where management will discuss the results and the execution of the company’s growth strategy. Notably, Anavex is developing treatments for a range of serious conditions, including Alzheimer's and Parkinson's disease, and has seen progress with its lead drug candidate, ANAVEX®2-73. The company's continual updates aim to keep stakeholders informed about its advancements and financial health.
Read more →AVXL▼ -6.4%on this news
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
Anavex Life Sciences Corp. announced the issuance of a new U.S. patent for ANAVEX®2-73, which includes various formulations aimed at treating neurodegenerative disorders. This patent, expected to last until at least July 2039, enhances the company's existing intellectual property portfolio. The new crystalline forms of the drug are designed to improve patient compliance and therapeutic efficacy.
Read more →AVXL▼ -6.4%on this newsshared move
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX 2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
Anavex Life Sciences Corp. has announced the issuance of a new U.S. Patent No. 12,180,174 for Anavex®2-73 (blarcamesine), which covers novel formulations for treating neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. This patent will remain valid until at least July 2039 and complements existing patents for the drug, enhancing its market position. The new crystalline formulations aim to improve patient compliance through various delivery methods, including transdermal patches. Anavex has demonstrated expertise in developing these formulations, which may offer improved efficacy and reduced side effects.
Read more →AVXL▲ +8.2%on this news
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
Anavex Life Sciences Corp. announced the publication of peer-reviewed results from a Phase IIb/III study of oral blarcamesine, demonstrating significant slowing of Alzheimer's disease progression. The study revealed a 36.3% reduction in clinical deterioration over 48 weeks, and the treatment showed a favorable safety profile with no neuroimaging adverse events. Blarcamesine is positioned as a potential novel oral therapy, offering a complement or alternative to injectable medications. The findings have been published in The Journal of Prevention of Alzheimer’s Disease, reinforcing the drug's promise in addressing early Alzheimer's pathology.
Read more →AVXL▼ -6.1%on this newsshared move
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
Anavex Life Sciences announced positive results from the ATTENTION-AD trial, demonstrating that over three years of treatment with blarcamesine significantly benefits early Alzheimer's disease patients. The trial showed improved cognition and function, with a favorable safety profile and no treatment-related deaths. Early initiation of treatment was highlighted as crucial for maximizing benefits.
Read more →AVXL▲ +6.2%on this news
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Anavex Life Sciences Corp. will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. The presentation will be led by President & CEO Christopher U Missling, PhD, and will be available via an audio webcast. The company specializes in developing therapies for neurodegenerative diseases, with its lead product demonstrating potential in Alzheimer's and other CNS disorders. Anavex's advances have gained attention due to their promising clinical trial results.
Read more →AVXL▲ +29.5%on this news· ran to +40% by day 3
Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease
Anavex Life Sciences Corp. announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for blarcamesine, a novel oral treatment for Alzheimer's disease. The acceptance is based on positive results from the ANAVEX®2-73-AD-004 trial, which showed that blarcamesine significantly slowed clinical decline in early Alzheimer's patients. The company aims to enhance patient access to this new treatment option in Europe.
Read more →AVXL▲ +29.5%on this news· ran to +40% by day 3shared move
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
Anavex Life Sciences Corp. has reported its fourth quarter financial results for fiscal year ending September 30, 2024, highlighting its submission of a Marketing Authorization Application for blarcamesine to the EMA. CEO Christopher U Missling emphasized the commitment to provide innovative treatment options for Alzheimer's disease, particularly focusing on their oral delivery system. The company also announced participation in key healthcare conferences for data presentations. However, Anavex reported an increase in net loss and expenses compared to the previous year, raising concerns about ongoing funding.
Read more →AVXL▲ +8.5%on this news
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024
Anavex Life Sciences Corp. has announced the release of its financial results for the fiscal year ending September 30, 2024, scheduled for December 23, 2024. A conference call will be held the same day to review these results and discuss the company's growth strategy. Anavex, focused on innovative treatments for various CNS disorders, has made significant strides with its lead drug candidate, ANAVEX®2-73, through successful phases of clinical trials. The company continues to explore potential treatment avenues for Alzheimer's, Parkinson's, and other conditions.
Read more →AVXLAnavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
Anavex Life Sciences will present new topline data from its long-term Phase IIb/III ATTENTION-AD Open-Label-Extension trial at the J.P. Morgan 2025 Healthcare Conference. The data will detail findings on the oral drug blarcamesine, which is evaluated for its benefits in early Alzheimer's disease. This presentation will reflect up to 144 weeks of continuous treatment, demonstrating Anavex's commitment to developing effective treatments for neurodegenerative disorders. Results from this study could signify advances in care for patients and families affected by Alzheimer's disease.
Read more →AVXLAnavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024
Anavex Life Sciences Corp. announced that Christopher U. Missling, CEO, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on December 4, 2024. The conference will feature over 600 industry experts discussing various healthcare verticals, which underscores the company's active role in advancing neurodegenerative disease therapies. Anavex's lead candidate, ANAVEX®2-73, shows promising results in clinical trials for treatments of Alzheimer's and Parkinson's diseases, among others.
Read more →AVXLAnavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA
Anavex Life Sciences has submitted the Marketing Authorization Application (MAA) for blarcamesine to the European Medicines Agency (EMA), marking a significant milestone in Alzheimer's disease treatment. Blarcamesine has shown clinically meaningful improvements over 48 weeks and could offer a convenient oral alternative with favorable safety compared to existing therapies. The submission aligns with the increasing demands for effective Alzheimer's treatments, especially as the number of affected individuals in Europe continues to rise.
Read more →AVXLAnavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal
Anavex Life Sciences Corp. announced the acceptance of a peer-reviewed manuscript detailing Phase IIb/III data on its investigational drug, oral blarcamesine, for early Alzheimer's disease. This significant milestone indicates the value of the company's findings for the scientific community. The publication is expected in late 2024 or early 2025, and regulatory submission to the European authorities is also anticipated within the current quarter. The manuscript aims to educate the medical community on the potential benefits of blarcamesine for Alzheimer's patients.
Read more →AVXL▲ +15.9%on this news· ran to +35% by day 3
Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
Anavex Life Sciences Corp. presented promising data from its Phase IIb/III Alzheimer’s trial of Blarcamesine at the CTAD Conference 2024. The study showed a significant 36.3% reduction in clinical decline over 48 weeks, with even better results in patients with the common SIGMAR1 wild type. The treatment demonstrated a good safety profile and does not require routine MRI monitoring. Anavex plans to submit for regulatory approval in Europe within the current quarter.
Read more →AVXLAnavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
Anavex Life Sciences has reported promising preliminary results from Part A of its Phase 2 study of ANAVEX®3-71 for schizophrenia. The study showed a dose-dependent effect on EEG biomarkers, indicating potential therapeutic benefits. Patients are currently being treated in Part B of the study, which aims to provide further data on efficacy and safety. Results from Part B are expected in early 2025.
Read more →AVXLAnavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX 3-71 for the Treatment of Schizophrenia
Anavex Life Sciences has announced positive preliminary results from Part A of its Phase 2 study for ANAVEX®3-71, aimed at treating schizophrenia. The study showed a dose-dependent pharmacodynamic effect on EEG biomarkers, indicating potential therapeutic benefits. Patients are currently being enrolled in Part B of the study, anticipated to provide more comprehensive data on the drug's efficacy and safety. The data from Part B is expected in the first half of 2025.
Read more →AVXL▼ -9.3%on this news
Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced that CEO Christopher U. Missling will present at the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. The presentation is aimed at highlighting the company's advancements in treating central nervous system diseases, particularly Alzheimer's and Parkinson's. Additionally, Missling will participate in a panel discussion focused on non-amyloid-targeted approaches in Alzheimer’s disease treatment. Anavex continues to develop its clinical pipeline, including potential therapies showing promise in preclinical studies.
Read more →AVXL▲ +5.7%on this news
Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
Anavex Life Sciences Corp. reported its financial results for Q3 fiscal 2024, highlighting positive developments in its clinical trials. Notably, results from a Phase 2b/3 trial of blarcamesine showed significant effectiveness in slowing cognitive decline in early Alzheimer's patients. The company also announced advancements in its schizophrenia and Parkinson's disease studies. However, it reported a net loss of $12.2 million for the quarter and increasing R&D expenses, which may present financial considerations moving forward.
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
Anavex Life Sciences Corp. will announce its fiscal 2024 third quarter financial results on August 6, 2024. The company will also host a conference call to review results and discuss its growth strategy. Anavex is known for developing therapeutics for neurodegenerative diseases and showcases positive outcomes in clinical trials for its lead drug candidate, ANAVEX®2-73. The event emphasizes Anavex's commitment to transparency with its shareholders.
Read more →AVXL▼ -10.4%on this newsshared move
Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference
Anavex Life Sciences has reported positive preclinical results for ANAVEX®2-73 in treating Fragile X Syndrome, a leading cause of autism. The findings indicate significant improvements in EEG biomarkers in a mouse model, suggesting the drug's potential to address cognitive and behavioral challenges. The company plans to initiate a clinical trial to further evaluate the drug's safety and efficacy.
Read more →AVXL▼ -10.4%on this newsshared move
Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX 2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference
Anavex Life Sciences Corp. announced promising results for ANAVEX®2-73 (blarcamesine) at the 19th NFXF International Fragile X Conference. The drug positively impacted EEG biomarkers in a Fragile X syndrome model, suggesting therapeutic potential for cognitive and behavioral issues associated with the disorder. The Company plans to begin a clinical trial to evaluate ANAVEX®2-73’s safety and efficacy in patients with Fragile X syndrome, expanding its focus on this significant unmet medical need. The findings reinforce the drug's potential as part of a precision medicine approach for neurodevelopmental disorders.
Read more →AVXLResults from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer’s Association Conference
Anavex Life Sciences presented positive results from its Phase IIb/III trial of blarcamesine at the Alzheimer's Association Conference. The study demonstrated that blarcamesine significantly slowed clinical decline in early Alzheimer's disease patients, with a notable safety profile. The company plans to submit for EMA approval in Q4 2024, highlighting the potential for broader access to this treatment.
Read more →AVXLAnavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Anavex Life Sciences Corp. (AVXL) will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024. CEO Christopher U. Missling is expected to highlight the company's progression in developing treatments for various neurodegenerative and neuropsychiatric disorders, including Alzheimer's and Parkinson’s diseases. Anavex has achieved important clinical trial milestones for its lead drug candidate, ANAVEX®2-73, which is undergoing testing for effectiveness in various conditions. The presentation will also be accessible via a live audio webcast on the company's website.
Read more →AVXLAnavex Life Sciences Announces Expansion of Leadership Team
Anavex Life Sciences Corp. has announced the expansion of its leadership team with the appointment of three senior executives who have extensive experience in drug development. Dr. Juan Carlos Lopez-Talavera is appointed as Senior Vice President, Head of Research and Development; Dr. Terrie Kellmeyer as Senior Vice President of Clinical Development; and Dr. Jeffrey Edwards as Vice President of Clinical Pharmacology and Science. This strategic move aims to enhance Anavex's capabilities in bringing innovative therapeutics to market for treating neurodegenerative and neuropsychiatric disorders.
Read more →AVXL▲ +8%on this news
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
Anavex Life Sciences Corp. announced that its CEO, Christopher U. Missling, will present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ on May 20, 2024. The company is known for developing therapeutics for neurodegenerative and neuropsychiatric disorders, with its lead candidate, ANAVEX®2-73, demonstrating potential in several clinical trials. The presentation will also be available via live webcast on the company’s website. Anavex continues to focus on advancing its drug candidates aimed at treating serious CNS diseases.
Read more →AVXLAnavex Life Sciences Corporation Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights – AVXL
Anavex Life Sciences Corporation is currently facing a class action securities fraud lawsuit involving allegations of misleading investors about clinical trial results. The lawsuit pertains to events between June 2021 and January 2024, following a significant drop in stock price after announced trial results that were later questioned by analysts. Furthermore, the company's candidate for Rett syndrome failed to meet primary endpoint significance, resulting in further declines in stock value and investor trust. Interested parties have until May 13, 2024, to participate in the lawsuit without upfront costs.
Read more →AVXLAnavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
Anavex Life Sciences reported its fiscal Q2 2024 financial results, highlighting positive developments in its clinical trials for Alzheimer's and schizophrenia. The company is encouraged by new FDA guidance for Alzheimer's treatment and has fully enrolled the first cohort for its schizophrenia trial. Despite a net loss of $10.5 million, Anavex remains committed to advancing its neurodegenerative disorder therapies.
Read more →AVXLANAVEX ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Anavex Life Sciences Corp. and Encourages Investors to Contact the Firm
Anavex Life Sciences Corp. is facing a class action lawsuit filed in the U.S. District Court for the Southern District of New York, involving investors who purchased its securities from June 2021 to January 2024. The lawsuit arose following questions regarding the validity of clinical trial results for its drug ANAVEX®2-73 and recent negative outcomes from another trial in pediatric patients with Rett syndrome. Following these events, Anavex's stock experienced significant declines of approximately 20% and 35%, respectively, prompting concerns among investors.
Read more →AVXLAnavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update Company to host a webcast today at 8:30 a.m. Eastern Time
Anavex Life Sciences Corp. reported its fiscal Q2 2024 financial results, highlighting a loss of $10.5 million compared to $13.1 million in the previous year. The company expressed optimism regarding new FDA guidance for Alzheimer's treatment, which may streamline development processes. Additionally, it announced the full enrollment of schizophrenia patients in a Phase 2 clinical trial. Despite these advancements, the company continues to experience significant operating losses, influencing its financial outlook.
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024
Anavex Life Sciences Corp. is set to announce its fiscal 2024 second quarter financial results on May 9, 2024. The announcement will be accompanied by a conference call, allowing management to review the results and discuss the company's growth strategy. Anavex is focused on therapeutics for neurodegenerative disorders and has recently completed several clinical trials for its lead drug candidate, ANAVEX®2-73. The company's ongoing research is bolstered by grants, including support from The Michael J. Fox Foundation for Parkinson's Research.
Read more →AVXLAnavex Life Sciences investors: Please contact the Portnoy Law Firm to recover your losses; May 13, 2024 deadline
Anavex Life Sciences Corp. is facing a lawsuit filed on behalf of investors who purchased its securities during the specified class period. The suit alleges that the company misrepresented its clinical trial data concerning the drug blarcamesine, aimed at treating Rett syndrome. Following the announcement of disappointing trial results on January 2, 2024, which were derived using an unprecedented statistical method, the stock price saw a sharp decline of 35%. Investors are being urged to connect with the Portnoy Law Firm for potential recovery of their losses.
Read more →AVXL▲ +6.1%on this newsshared move
ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Anavex Life Sciences Corporation Investors of Upcoming Deadline
Anavex Life Sciences Corporation faces a class action lawsuit alleging securities fraud due to questionable reporting in clinical trial results for its drug blarcamesine. The suit claims that Anavex misused statistical methods in its studies, leading to substantial stock price losses exceeding 35%. Investors who acquired shares from February 1, 2022, to January 1, 2024, are urged to file a lead plaintiff motion before the May 13, 2024 deadline. The litigation underscores serious concerns regarding the company's transparency and integrity in clinical trial reporting.
Read more →AVXLANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Anavex Life Sciences Corporation
Anavex Life Sciences Corporation is currently facing a securities class action lawsuit filed in the U.S. District Court for the Southern District of New York. The lawsuit alleges violations related to misrepresentations regarding trial results for the company's drug, blarcamesine, especially concerning its efficacy in treating patients with Rett syndrome. Anavex's stock price has significantly dropped due to recent underwhelming results from clinical trials, prompting concerns among investors and legal actions. Affected investors have until May 13, 2024, to file a lead plaintiff motion in this case.
Read more →AVXLAnavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
Anavex Life Sciences Corp. will present at the Noble Capital Markets Virtual Healthcare Equity Conference on April 18, 2024. Christopher U Missling, the President & CEO, is scheduled to speak at 1:30 PM ET, providing insights into the company’s innovative therapeutics for neurodegenerative and neurodevelopmental disorders. Anavex's lead drug candidate, ANAVEX®2-73, has successfully completed multiple clinical trials for Alzheimer's disease, showcasing its potential in treating various CNS disorders. The presentation will be accessible via a live audio webcast on the company's website.
Read more →AVXLAnavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights – AVXL
Anavex Life Sciences Corporation (NASDAQ: AVXL) is facing a lawsuit for securities law violations related to its clinical trial announcements. The class period for shareholders spans from February 1, 2022, to January 1, 2024, during which the company made statements about positive outcomes from its Phase 2b/3 clinical trial for blarcamesine. However, analysts have raised concerns about the validity of these results and the company's shifting approaches regarding trial designs. Following poor trial results and stock price declines, shareholders are advised to register for potential participation in the class action lawsuit by May 13, 2024.
Read more →AVXLAnavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
Anavex Life Sciences Corp. (Nasdaq: AVXL) announced its participation in the 23rd Annual Needham Virtual Healthcare Conference, set for April 8-11, 2024. CEO Christopher U Missling, PhD, will present on April 8th at 8:45 AM (ET). The conference aims to spotlight the company's developments in therapeutics for neurodegenerative disorders. Anavex's lead candidate, ANAVEX®2-73, has demonstrated success in various clinical trials, particularly for Alzheimer's disease and Parkinson's disease dementia.
Read more →AVXL▼ -5.7%on this news
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Anavex Life Sciences has commenced a Phase 2 clinical trial for ANAVEX®3-71 in schizophrenia, screening the first patient ahead of schedule. This trial aims to evaluate the drug's efficacy across various symptom domains of schizophrenia, leveraging a dual mechanism of action that targets SIGMAR1 and M1 receptors. The study follows positive Phase 1 results and seeks to address significant unmet needs in schizophrenia treatment.
Read more →AVXL▼ -5.7%on this newsshared move
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX 3-71 in Schizophrenia
Anavex Life Sciences Corp. has commenced a U.S. FDA-cleared Phase 2 clinical trial of ANAVEX®3-71 for schizophrenia, having screened its first patient ahead of schedule. This trial aims to evaluate the drug’s effects on various symptom domains of the disorder while leveraging novel biomarkers. Following favorable Phase 1 results in healthy volunteers, the company's dual mechanism of action targets both SIGMAR1 and M1 receptors, potentially improving treatment options for schizophrenia.
Read more →AVXLANAVEX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Anavex Life Sciences Corp. and Encourages Investors to Contact the Firm
A class action lawsuit has been filed against Anavex Life Sciences Corp. for allegedly misleading investors regarding clinical trial results. The lawsuit concerns securities purchased between February 1, 2022, and January 1, 2024. Following the announcement of positive topline results from a key clinical trial, stock prices fell significantly, amid criticisms of the trial's design and results. Additionally, a subsequent announcement regarding a failed pediatric trial led to another substantial drop in stock value.
Read more →AVXLANAVEX LIFE SCIENCES CORPORATION SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Anavex Life Sciences Corporation (NASDAQ: AVXL)
Anavex Life Sciences Corporation is facing a securities class action lawsuit filed by Bernstein Liebhard LLP, accusing the company of violating the Securities Exchange Act of 1934. The lawsuit is linked to the handling of clinical trial results for blarcamesine, a treatment for central nervous system disorders, including Rett syndrome. Following the announcement of the results from the Excellence study, which failed to achieve statistical significance on most measures, Anavex's stock saw a drastic decline of over 35%. Investors are encouraged to discuss their rights and options regarding the lawsuit.
Read more →AVXLAnavex Life Sciences Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Anavex Life Sciences Corp. is being investigated by Block & Leviton for possible securities law violations after the company's candidate ANAVEX®2-73 showed disappointing results in its Phase 2/3 EXCELLENCE clinical trial for Rett syndrome. Following the trial, Anavex's stock experienced a significant drop of around 35%. Investors who have incurred losses are being urged to reach out to Block & Leviton to explore recovery options. The firm is well-regarded for representing defrauded investors in securities litigation.
Read more →AVXLAnavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
Anavex Life Sciences Corp. announced its participation in the 44th Annual TD Cowen Health Care Conference scheduled for March 4-6, 2024. CEO Dr. Christopher U Missling will present at the event in Boston, MA. Anavex focuses on developing therapeutics for neurodegenerative disorders, with their lead candidate, ANAVEX®2-73, having completed several clinical trials for Alzheimer's disease and Parkinson's disease. A live audio webcast of the presentation will be accessible on their website.
Read more →AVXLAnavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update
Anavex Life Sciences Corp. reported its fiscal 2024 first quarter results, highlighting significant advances in the treatment of neurodegenerative diseases, particularly with its lead candidate blarcamesine for Alzheimer's disease. The company has initiated a Marketing Authorisation application with the EMA, which could enhance market access in the EU. Financially, Anavex reported a net loss of $8.6 million for the quarter, a decrease from the previous year, but also indicated reduced research expenses. Ongoing clinical trials for various disorders are also detailed, affirming the company's commitment to improving treatment options.
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
Anavex Life Sciences Corp. has announced that it will release its financial results for the fiscal quarter ended December 31, 2023, on February 7, 2024. During a conference call, management will discuss the results and provide updates on the company's growth strategy. The company has a pipeline focused on developing new therapeutics for neurodegenerative and neurodevelopmental disorders, which includes promising candidates undergoing clinical trials.
Read more →AVXLAnavex Life Sciences Reports Publication of ANAVEX 3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX 3-71 in Humans
Anavex Life Sciences Corp. has published a peer-reviewed study confirming the pharmacokinetic dose proportionality of ANAVEX 3-71 in humans, demonstrating safety and linear pharmacokinetics. The study finds that food intake has no effect on the drug's pharmacokinetics, and further supports the drug's development for treating conditions like Alzheimer's and Schizophrenia. CEO Christopher U. Missling highlights the company's commitment to advancing ANAVEX 3-71's clinical trials, with a Phase 2 trial in Schizophrenia forthcoming.
Read more →AVXLAnavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX 3-71 in Schizophrenia
Anavex Life Sciences Corp. announced the initiation of a placebo-controlled Phase 2 clinical trial for its compound ANAVEX®3-71 to treat schizophrenia, with the study expected to commence in Q2 2024. This trial aims to evaluate the efficacy of ANAVEX®3-71 in addressing the positive, negative, and cognitive symptoms associated with schizophrenia, utilizing established clinical outcome measures. The drug operates through a dual mechanism of action, potentially providing a new treatment option that avoids the side effects commonly seen with current antipsychotic medications.
Read more →AVXL▲ +9.2%on this news
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX 2-73) for Treatment of Neurodevelopmental Disorders
Anavex Life Sciences Corp. has been granted a new U.S. Patent No. 11,839,600 for its drug candidate ANAVEX®2-73 (blarcamesine), aimed at treating various neurodevelopmental disorders linked to mutations in the MeCP2 gene. This patent expands the drug's coverage for symptoms associated with conditions such as Rett syndrome and autism spectrum disorder and is expected to remain in force until at least January 2037. The company's management emphasized this development as a sign of their commitment to advancing effective therapies for neurodevelopmental and neurological diseases.
Read more →AVXL▲ +8%on this newsshared move
Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Anavex Life Sciences Corp. (Nasdaq: AVXL) will participate in the 42nd Annual J.P. Morgan Healthcare Conference, with its CEO scheduled to present on January 11, 2024. The event will take place at the Westin St. Francis in San Francisco, CA, and a live audio webcast will be provided for interested investors. Anavex is a clinical-stage biopharmaceutical company focused on innovative therapies for neurodegenerative and neurodevelopmental disorders.
Read more →AVXL▼ -35.1%on this newsshared move
Anavex Life Sciences Provides an Update on Rett Syndrome Program
Anavex Life Sciences announced topline results from its Phase 2/3 EXCELLENCE clinical trial evaluating ANAVEX®2-73 in pediatric patients with Rett syndrome. The study reported improvements in key co-primary endpoints, with significant RSBQ improvements observed at 4 weeks. However, the primary endpoint of the Clinical Global Impression - Improvement scale was not met due to a high placebo effect that may have obscured the compound's therapeutic benefits. Despite this, the company noted a favorable safety profile for ANAVEX®2-73 with high continuation rates into an open-label extension study.
Read more →AVXL▼ -11.1%on this news
Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX 2-73 from AVATAR Study in Patients with Rett Syndrome
Anavex Life Sciences Corp. has released the first comprehensive clinical gene pathway data from its ANAVEX®2-73-RS-002 AVATAR study focused on Rett syndrome. The study, which included 33 patients and utilized whole genome and exome analysis, suggests that ANAVEX®2-73 can address key metabolic components associated with Rett syndrome. Notably, the transcriptomics analysis revealed significant differential gene expression in treated patients, indicating potential pathways related to neurodevelopmental diseases. Anavex's CEO emphasized the importance of these findings for understanding Rett syndrome and their drug's therapeutic potential.
Read more →AVXL▲ +13.2%on this newsshared move
Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease
Anavex Life Sciences Corp. has been granted the eligibility by the CHMP to submit a Marketing Authorisation Application for blarcamesine, intended for Alzheimer's disease. This marks a significant step as it allows for a centralized application process to market the treatment across EU member states. Anavex plans to submit this application in early 2024, capitalizing on the large population of Alzheimer's patients in Europe. The clinical trial data suggests blarcamesine not only improves dementia symptoms but also reduces pathological amyloid aggregation and brain volume loss.
Read more →AVXL▼ -10%on this news
Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update
Anavex Life Sciences Corp. has reported its financial results for the fiscal year ending September 30, 2023, highlighting the initiation of a Marketing Authorisation application to the EMA for its Alzheimer's treatment, blarcamesine. The company will present full data from its Phase 2b/3 trial in an upcoming peer-reviewed journal. Additionally, Anavex maintains a strong cash position of $151 million while continuing to invest in multiple pipeline trials across several neurodegenerative disorders. Despite a net loss in the fourth quarter, the company remains focused on developing innovative therapeutic solutions.
Read more →AVXL▲ +5.5%on this newsshared move
Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
Anavex Life Sciences Corp. announced it will release its financial results for the fiscal year ending September 30, 2023, on November 27, 2023. The announcement will be followed by a conference call where management will discuss the results and the company's growth strategy. The call will include a question-and-answer session, allowing for further engagement with stakeholders. Anavex is focused on developing treatments for neurodegenerative diseases and has several candidates in various stages of clinical trials.
Read more →AVXLAnavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX 2-73) for Treatment of Insomnia or Anxiety
Anavex Life Sciences Corp. announced that it has received a U.S. Patent for its lead drug candidate, ANAVEX®2-73 (blarcamesine), which is now protected for the treatment of insomnia, anxiety, and agitation. This patent significantly extends the company’s intellectual property portfolio, covering various administration routes and co-morbidities related to Alzheimer's and Parkinson's diseases. With protection lasting at least until 2037, the patent secures a competitive edge for Anavex in the neurodegenerative disorder treatment market.
Read more →AVXL▲ +11.6%on this newsshared move
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency (EMA)
Anavex Life Sciences Corp. has initiated the regulatory submission process for its oral Alzheimer's treatment, blarcamesine, to the European Medicines Agency. This follows a meeting with EMA representatives to discuss the clinical program's results. Anavex aims to provide a patient-centric, convenient treatment that doesn't require complex administration procedures, addressing the urgent need for such options in Europe. The company reports positive clinical results, including significant improvements in dementia symptoms and reduced brain volume loss.
Read more →AVXLAnavex Life Sciences Appoints Senior VP of Regulatory Affairs
Anavex Life Sciences Corp. has announced the appointment of David Goldberger as the new Senior Vice President of Regulatory Affairs. Goldberger brings over 40 years of experience from his previous role at Otsuka Pharmaceuticals, where he led regulatory efforts for CNS products. He will succeed Emmanuel O Fadiran, who is retiring. The company expressed optimism about Goldberger's expertise aiding in the development of its drug candidates targeting neurodegenerative and neurodevelopmental diseases, which have shown promising results in various clinical trials.
Read more →AVXL▲ +9%on this news
Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX 3-71 to Prevent Cognitive Decline in Alzheimer’s Disease
Anavex Life Sciences reported a new publication demonstrating the efficacy of ANAVEX®3-71 in preventing cognitive decline associated with Alzheimer’s disease. In a transgenic rat model, the drug significantly reduced amyloid plaques and neuroinflammation over a 7-month treatment period, with positive effects persisting after a lengthy washout phase. This peer-reviewed publication in the journal Neurobiology of Aging adds credibility to the potential disease-modifying properties of ANAVEX®3-71 and affirms the company's commitment to advancing therapies for neurodegenerative disorders.
Read more →AVXLAnavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX 2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration
Anavex Life Sciences Corp. announced positive results from its Phase 2b/3 trial of blarcamesine for early Alzheimer's disease. The study, which included 508 participants, demonstrated a statistically significant slowing in cognitive decline and a reduction in pathological amyloid beta levels. Additionally, the treatment showed a significant reduction in brain atrophy on MRI scans. Blarcamesine's safety profile was favorable, with transient mild to moderate side effects reported.
Read more →AVXLAnavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board
Anavex Life Sciences Corp. has appointed Prof. Dr. Marwan N Sabbagh, MD, as the Chairman of its Scientific Advisory Board. Dr. Sabbagh brings significant expertise in Alzheimer's disease, being a prominent neurologist and researcher in the field. His role is expected to support the development of Anavex's lead drug candidate, blarcamesine (ANAVEX®2-73), which has shown positive clinical results in treating Alzheimer's. The appointment underscores Anavex's commitment to addressing the unmet medical needs associated with neurodegenerative diseases.
Read more →AVXLAnavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results
Anavex Life Sciences Corp. (AVXL) reported its fiscal third-quarter financial results for 2023, highlighting a strong cash position and upcoming pivotal clinical trial data. The company is set to release crucial top-line data from its pediatric trial of ANAVEX®2-73 and preliminary results for its Alzheimer’s disease study later this year. Recent publications have underscored the safety of its drug candidates, while financial results indicated a net loss compared to the prior year, despite stable administrative expenses. The company continues to seek advancements in neurodevelopmental and neurodegenerative disorders.
Read more →AVXL▼ -6.6%on this newsshared move
Anavex Life Sciences Reports Publication of ANAVEX 3-71 in Clinical Journal Confirming ANAVEX 3-71 Clinical Cardiovascular Safety
Anavex Life Sciences Corp. reported the publication of findings from the ANAVEX®3-71 first-in-human study in Clinical Pharmacology in Drug Development, confirming the drug's cardiovascular safety. The study evaluated the drug's effects on ECG parameters and found no clinically relevant issues at doses ranging from 5 to 200 mg. This data broadens the safety assurance for ANAVEX®3-71 and supports Anavex's ongoing drug development efforts. Looking ahead, Anavex is set to begin Phase 2 clinical trials for Schizophrenia later this year.
Read more →AVXLAnavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023
Anavex Life Sciences Corp. will participate in the BTIG Virtual Biotechnology Conference 2023 with Christopher U. Missling, PhD, hosting a fireside chat. The event is scheduled for August 7, 2023, at 12:30 pm ET. Anavex is known for developing therapeutics for neurodegenerative diseases, including Alzheimer's and Parkinson's, with its lead candidate, ANAVEX®2-73, showing promising clinical trial results. The company also highlights the potential of its other candidate, ANAVEX®3-71, in addressing Alzheimer's disease pathologies.
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023
Anavex Life Sciences Corp. is scheduled to announce its fiscal 2023 third quarter financial results on August 8, 2023. The company will host a conference call to discuss these results and provide an update on its growth strategy. Anavex, focused on therapeutics for neurodegenerative disorders, has seen positive developments with its lead drug candidate, ANAVEX®2-73, which has completed several successful clinical trials. The announcement comes as the company continues to engage with stakeholders through various channels.
Read more →AVXLAnavex Life Sciences and Partex Group Announce Strategic Partnership to Leverage AI for Drug Development and Healthcare Sales Marketing Building a Patient-Centric Digital Ecosystem
Anavex Life Sciences has announced a strategic partnership with Partex Group to utilize Partex's AI technology in drug development aimed at enhancing patient experiences in CNS indications. This collaboration will integrate a precision medicine approach while focusing on a patient-centric digital ecosystem. Key initiatives include the co-development of a disease-focused patient app and AI-driven healthcare sales marketing strategies. Both companies believe that this partnership could lead to improvements in treatment options and the overall future of biopharmaceutical business models.
Read more →AVXLAnavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Anavex Life Sciences Corp. will present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference on June 26, 2023. Christopher U. Missling, PhD, CEO of Anavex, will participate in a fireside chat during the event. The company focuses on developing therapeutics for neurodegenerative and neurodevelopmental disorders, and its lead drug candidate, ANAVEX®2-73, has shown significant promise in clinical trials. The participation in the conference is expected to enhance the company's visibility in the biopharmaceutical sector.
Read more →AVXLANAVEX 2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome
Anavex Life Sciences Corp. has announced that Health Canada has granted compassionate use authorization for their drug ANAVEX®2-73 (blarcamesine) for pediatric patients with Rett syndrome. This authorization follows a successful Open-Label Extension study and allows patients to continue receiving treatment after the study's completion. Additional compassionate use applications are also in progress in the United Kingdom and Australia, enhancing access to this treatment for patients globally. The approval is significant as there are currently no specific treatments for Rett syndrome available in Canada.
Read more →AVXL▼ -5.4%on this newsshared move
Anavex Life Sciences Reports Publication in Medical Journal Signifying Continued Commitment for Improvement of the Rett Syndrome Caregiver Outcome Measure RSBQ
Anavex Life Sciences Corp. announced the publication of a new study in the American Journal on Intellectual and Developmental Disabilities regarding the Rett Syndrome Behaviour Questionnaire (RSBQ). This study, involving over 600 patients, provides significant insights into the behavior and treatment of individuals with Rett syndrome, proposing revised structures for improved clinical application. Conducted in collaboration with several international databases, this research contributes important metrics for clinical trials and caregiving strategies in Rett syndrome. Anavex anticipates positive topline data from its ongoing pediatric clinical trial utilizing the RSBQ.
Read more →AVXLAnavex Life Sciences Announces Completion of ANAVEX( )2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Anavex Life Sciences has completed the dosing of all participants in its Phase 2/3 EXCELLENCE study for ANAVEX®2-73 (blarcamesine) in pediatric patients with Rett syndrome. The study's results, which are anticipated in the latter half of this year, follow successful earlier phases in adult patients. This development reflects the company's ongoing commitment to addressing the severe impacts of Rett syndrome, a genetic neurodevelopmental disorder.
Read more →AVXLANAVEX Announces Issuance of New U.S. Intellectual Property Compositions Patent for ANAVEX 2-73 (blarcamesine)
Anavex Life Sciences Corp. has announced the issuance of a new U.S. patent for ANAVEX 2-73 (blarcamesine), enhancing its patent protection for specific crystal forms of the compound used in clinical trials targeting neurological disorders. This new patent is expected to remain valid until at least October 2036 and expands on existing protections, ensuring that the methods for preparing these forms are also covered. The patent is significant as all ongoing trials for ANAVEX 2-73 utilize these patented crystal forms as the active ingredients.
Read more →AVXL▲ +7.8%on this news
Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results
Anavex Life Sciences Corp. reported its fiscal 2023 second quarter financial results, highlighting promising preliminary efficacy results from the ANAVEX®2-73-AD-004 study aimed at Alzheimer’s disease. The company is preparing to engage with regulatory agencies concerning an Accelerated Approval Pathway based on these results. Anavex also expects to release top-line data from its pediatric Phase 2/3 clinical trial in the latter half of 2023. Financially, the company noted a net loss of $13.1 million for the quarter, alongside an increase in research and development expenses.
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023
Anavex Life Sciences Corp. (AVXL) will announce its fiscal 2023 second quarter financial results on May 9, 2023, followed by a conference call for management to review the results and discuss the company's growth strategy. The company focuses on developing therapeutics for neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Its lead drug candidate, ANAVEX®2-73, has completed several clinical trials, showing promise in treating these conditions. The announcement emphasizes Anavex's commitment to innovation and transparency.
Read more →AVXLAnavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX 2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension
Anavex Life Sciences Corp. has been granted a new U.S. Patent No. 11,622,955, which expands the patent portfolio for its drug ANAVEX 2-73 (blarcamesine) to include treatment for systolic hypertension. This new patent covers treatment methods for managing elevated systolic blood pressure, an issue affecting nearly half of adults in the U.S. The company expects the patent to remain effective until at least November 2038. This development reinforces Anavex's commitment to protecting and expanding its intellectual property related to ANAVEX 2-73, highlighting its potential commercial opportunities in addressing high blood pressure.
Read more →AVXLAnavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Anavex Life Sciences Corp. announced that its CEO, Dr. Christopher U. Missling, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023. The company focuses on developing therapeutics for neurodegenerative disorders, with promising candidates like ANAVEX®2-73 and ANAVEX®3-71 showing potential efficacy. The announcements underline the company's aim to attract investor interest while also acknowledging the inherent risks associated with forward-looking statements.
Read more →AVXLAnavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023
Anavex Life Sciences Corp. announced that their President and CEO, Christopher U Missling, PhD, will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023. The company is focused on developing therapeutics for neurodegenerative and neurodevelopmental disorders, including Alzheimer's and Parkinson's disease. Anavex has shown promising results with its lead drug candidate, ANAVEX®2-73, having successfully completed multiple clinical trials. The presentation aims to increase the company's visibility within the healthcare community.
Read more →AVXLANAVEX 2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia
Anavex Life Sciences Corp. reported positive results from its 48-week open-label extension study of ANAVEX®2-73 for patients with Parkinson's disease dementia. The study achieved both primary and secondary objectives, demonstrating improvements in clinical symptoms over time. Following the study, patients requested ongoing access to the treatment, and additional supportive research from the Michael J. Fox Foundation was noted. However, the results must be evaluated carefully due to the small sample size and the impact of a 'drug holiday' between study phases.
Read more →AVXLAnavex Life Sciences Appoints Former FDA Lead Neurology Statistician as Vice President Head of Biostatistics
Anavex Life Sciences Corp. has appointed Dr. Kun Jin as Vice President and Head of Biostatistics. Dr. Jin brings over 27 years of experience at the FDA, specifically handling statistical reviews for neurological drug products. His expertise is expected to support Anavex's clinical development and regulatory efforts, particularly for therapies targeting Alzheimer's and other CNS disorders. The leadership positive remarks emphasize the importance of his appointment at this pivotal time as the company works towards commercialization of its innovative therapeutics.
Read more →AVXL▲ +5.8%on this news
Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results
Anavex Life Sciences Corp. (Nasdaq: AVXL) released its financial results for the first quarter of fiscal 2023, noting a net loss of $13.0 million. The company highlighted progress in its Alzheimer's disease trial, with data suggesting significant clinical benefits from its lead drug ANAVEX®2-73 (blarcamesine). Additionally, Anavex announced upcoming dataset presentations for multiple CNS disorders including Parkinson's disease and Rett syndrome. Overall, the company maintains a strong financial position with $143.6 million in cash, despite an increase in operational losses.
Read more →AVXLAnavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX 2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Anavex Life Sciences has announced that it has exceeded its enrollment target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 clinical trial aimed at treating Rett syndrome. A total of 92 patients aged 5 to 17 have been enrolled, and topline results are anticipated later this year. The trial examines the safety and efficacy of the oral drug, which has already received various designations from the FDA, indicating its therapeutic potential within this challenging disease area.
Read more →AVXL▲ +8.2%on this newsshared move
Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on Tuesday February 7, 2023
Anavex Life Sciences Corp. plans to release its financial results for the first quarter of fiscal 2023 on February 7, 2023. This announcement includes a conference call scheduled for the same day, where management will discuss the results and the company's growth strategy. Anavex continues to focus on developing innovative treatments for neurodegenerative disorders like Alzheimer's and Parkinson's disease. Recent successful trials of its lead drug candidate, ANAVEX®2-73, underline the potential of its therapeutic approach.
Read more →AVXLAnavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXL▲ +13.3%on this newsshared move
Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXL▲ +35.9%on this news
Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLANAVEX 2-73 ( BLARCAMESINE ) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS, SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER'S DISEASE R
ANAVEX 2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS, SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER'S DISEASE Robust, Statistically Significant and Clinically Meaningfu
Read more →AVXL▼ -23.5%on this newsshared move
Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neu
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXL▲ +5.9%on this news· ran to +26% by day 3
Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference 2022
NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 (blarcamesine) for the Treatment of Fragile X Syndrome
NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXL▲ +17.8%on this news
Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX 2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022
NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX 2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer's Disease
Mechanism of Action of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) is the activation of SIGMAR1 Endogenous increase in SIGMAR1 activation as a compensatory mechanism against early Alzheimer's disease Top line results of randomized, placebo-controlled Phase 2b/3 study AN
Read more →AVXL▼ -5.7%on this news
Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Third Quarter Financial Results
Company to host a webcast today at 4:30 p.m. Eastern Time NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neu
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday August 9, 2022
NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Announces Long-lasting Effect of ANAVEX 3-71 Preventing Cognitive Decline in a Transgenic Rat Model of Alzheimer’s Disease at AAIC 2022
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX 2-73 at AAIC 2022
Expression levels of pathological dysregulated neurodegenerative genes of both Alzheimer’s and Parkinson’s disease were significantly restored by the therapeutic effect of ANAVEX®2-73 (p<0.005) These findings will facilitate contextualization of upcoming readout of ANAVEX®2-73 P
Read more →AVXL▲ +7.3%on this news· ran to +20% by day 3
Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release
NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex’s Publication Supports Clinical Biomarker for ANAVEX 2-73 in Fragile X Syndrome
NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXL▲ +6.3%on this news
Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Al
Read more →AVXLAnavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results
Company to host a webcast today at 4:30 p.m. Eastern Time NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neur
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tuesday May 10, 2022
NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Al
Read more →AVXLAnavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting
NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXL▼ -6.6%on this newsshared move
Anavex Life Sciences Invited to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences to Present at the Needham Virtual Healthcare Conference
NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences to Participate in the Cantor Virtual Rare Orphan Disease Summit
NEW YORK, March 28, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXL▲ +5.7%on this news· ran to +30% by day 3
Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from ANAVEX 2-73-PDD-001 Parkinson’s Disease Dementia Study at AD/PD™ 2022 International Conference
All MDS-UPDRS Part I, II, III, IV sub-scores improved, including substantial majority of individual items between 71% and 92% SIGMAR1 mRNA expression significantly increased in ANAVEX®2-73-treated patients vs placebo (p=0.035) and was significantly associated with improvements o
Read more →AVXL▲ +9.5%on this news
Anavex Life Sciences to Participate in the Annual Needham Virtual Neuroscience Forum
NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences Announces Change of Auditor to Grant Thornton
Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP NEW YORK - March 4, 2022 - Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neur
Read more →AVXL▲ +7.7%on this news
Anavex Life Sciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXL▲ +5.8%on this newsshared move
Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 First Quarter Financial Results
Company to host a webcast today at 4:30 p.m. Eastern Time NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neu
Read more →AVXLAnavex Life Sciences Provides Supplemental Information on ANAVEX 2-73 ( Blarcamesine ) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome
Anavex Life Sciences Provides Supplemental Information on ANAVEX 2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome NEW YORK - February 4, 2022 - Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stag
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2022 First Quarter Financial Results on Wednesday, February 9, 2022
NEW YORK, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Corp. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
BOSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) for potential securities law violations. Investors who have lost money in their Anavex Life Sciences Corp. investment should contact the firm to learn more about h
Read more →AVXL▼ -15.6%on this newsshared move
ANAVEX 2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome
Primary and all secondary efficacy and safety endpoints met, with consistent improvements in RSBQ AUC (p = 0.037), ADAMS (p = 0.010) and CGI-I (p = 0.037) response Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome sym
Read more →AVXLAnavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX 3-71
Study reached primary and secondary endpoints of safety, respectively ANAVEX®3-71 well tolerated as oral administration in all dose cohorts No serious adverse events or dose-limiting toxicities observed Data provide early clinical proof of ANAVEX®3-71 having same pharmacokinet
Read more →AVXLAnavex Life Sciences Promotes Walter E Kaufmann, M.D. to Chief Scientific Officer and Appoints Edward R Hammond, M.D., M.P.H., Ph.D., as Chief Medical Officer
NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXL▼ -5.4%on this newsshared move
Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences to Present at 40th Annual J.P. Morgan Healthcare Conference
NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXL▲ +5.1%on this news
Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference
NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXL▲ +5.7%on this newsshared move
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results
NEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wednesday, November 24, 2021
NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Announces Participation at Upcoming Lausanne VIII Workshop Panel - Building Global Momentum for Interventions in Alzheimer’s Disease
NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference
NEW YORK, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX 2-73 in Patients with Alzheimer’s Disease
NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021
NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market
Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market NEW YORK - September 27, 2021 - Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatme
Read more →AVXLAnavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference
NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences Announces Publication of Foundational Data for ANAVEX 2-73 (blarcamesine) in Fragile X Syndrome (Autism)
Published in Scientific Reports, Results Highlight Reversal of Hyperactivity and Restoration of Associative Learning and Reduction of Anxiety, Phenotypes Associated with Fragile X Syndrome Positron emission tomography (PET) Establishes ANAVEX®2-73’s Dose Dependent SIGMAR1 Recept
Read more →AVXL▲ +7.1%on this news
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results
Total of 509 Patients Enrolled in Confirmatory Late-stage Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2/3 AVATAR Clinical T
Read more →AVXL▲ +10.7%on this news
Anavex Life Sciences to Announce Fiscal 2021 Third Quarter Financial Results on Thursday, August 12, 2021
NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021
NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Announces ANAVEX 2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease Dementia
ANAVEX®2-73 treatment resulted in significant increase in the expression of the SIGMAR1 mRNA biomarker that significantly correlated with improvements in the primary and secondary clinical efficacy endpoints CoA (p = 0.029) and MDS-UPDRS Part III (p = 0.024) and MDS-UPDRS Total (
Read more →AVXLAnavex Life Sciences Announces Closing of $50 Million Registered Direct Offering
NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Announces $50 Million Registered Direct Offering
Anavex Life Sciences Announces $50 Million Registered NEW YORK - June 22, 2021 - Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and
Read more →AVXLAnavex Life Sciences Announces ANAVEX 2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome
ANAVEX®2-73 treatment resulted in significant increase in the expression of the SIGMAR1 mRNA biomarker that significantly correlated with improvements in the two primary clinical efficacy endpoints RSBQ (p = 0.035) and CGI-I (p = 0.029) Data strengthens milestone to advance regu
Read more →AVXLAnavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX 2-73 (blarcamesine) and ANAVEX 3-71 (AF710B) related to the Treatment of Alzheimer's Disease
NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX 2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease
NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX 2-73 (blarcamesine) for the Treatment of Cardiac Dysfunctions
NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of Directors
Strengthening Board of Directors with Expertise in Innovative Product Launches NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for
Read more →AVXLAnavex Life Sciences Reports Fiscal 2021 Second Quarter Financial Results And Business Outlook
NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Al
Read more →AVXLAnavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit
NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Al
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2021 Second Quarter Financial Results and Business Outlook on Thursday, May 13, 2021
NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Al
Read more →AVXLAnavex Life Sciences Appoints Former FDA Officer as Senior Vice President for Nonclinical Development
NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Al
Read more →AVXLAnavex Life Sciences to Present at the B. Riley Securities’ Virtual Neuroscience Conference
NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials of ANAVEX 2-73 in Patients with Rett Syndrome
NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences to Present at the 20th Annual Needham Virtual Healthcare Conference
NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences Announces Participation at Upcoming World EPA - Evidence, Pricing and Access - Congress 2021
NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences Reports ANAVEX 2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical Trials in a New Publication in Medical Journal titled “Future Avenues for Alzheimer’s Disease Detection and Therapy”
NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences to Present at the H.C. Wainwright Global Life Sciences Conference
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease Day
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021
NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Reports Fiscal 2021 First Quarter Financial Results And Business Outlook
NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021
NEW YORK, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX 2-73 (blarcamesine) in People with Parkinson’s Disease
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect Conference
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates Conference Call and Webcast Today at 4:30 p.m.
Life Sciences Reports Fiscal 2020 Year End Financial Results Clinical Program Updates Call and Webcast Today at 4:30 p.m. ET YORK - December 28, 2020 - Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020
NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Announces Webinar on Rett Syndrome and ANAVEX 2-73 (Blarcamesine) Phase 2 Data hosted by Ladenburg Thalmann & Co.
NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Announces ANAVEX 2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome
Primary safety, pharmacokinetics and secondary efficacy endpoints met, with consistent improvements in RSBQ Total scores and CGI-I Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome symptoms and correlated with changes
Read more →AVXLAnavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims Covering ANAVEX 2-73 (blarcamesine) for the Treatment of Rett Syndrome and other Neurodevelopmental Disorders
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference
NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLProof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX 2-73 ( blarcamesine ) in Parkinson's Disease Dementia Presented at CTAD 2020 Conference Statistically significant improvements in CDR system Cogni
of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX 2-73 (blarcamesine) in Parkinson's Disease Dementia Presented at CTAD 2020 Conference significant improvements in CDR system Cognitive Domain of Attention assessed by Choice Reaction Time (p = 0.039) and Digi
Read more →AVXLAnavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX 2-73 ( blarcamesine ) in Parkinson's Disease Dementia Clinically meaningful, dose-dependent, and s
Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX 2-73 (blarcamesine) in Parkinson's Clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) c
Read more →AVXLAnavex Life Sciences Announces Completion of ANAVEX 2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences to Present at Upcoming Global Healthcare Conferences
NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for Clinical Trial of ANAVEX 2-73 (Blarcamesine) in Patients with Parkinson’s Disease
NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business Updates
NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX 2-73 (blarcamesine) for Alzheimer’s Disease Patients
NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2020 Third Quarter Financial Results on Thursday, August 6th, 2020
NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX 3-71 (AF710B)
NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX 2-73 (Blarcamesine) in Patients with Rett Syndrome
NEW YORK, July 01, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX 2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial
NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX 2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s Disease
NEW YORK, June 04, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX 3-71 (AF710B)
NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Al
Read more →AVXLAnavex Life Sciences Reports Fiscal 2020 Second Quarter Financial Results And Provides Business Updates
NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Al
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results on Thursday, May 7th, 2020
NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Al
Read more →AVXLAnavex Life Sciences Announces Publication of Clinical Data for ANAVEX 2-73 (blarcamesine) in Alzheimer’s Disease
Published in Alzheimer's & Dementia Journal, Results Highlight ANAVEX®2-73 (blarcamesine) Clinical Study, the First Reported Genome-Wide Search for Biomarkers Associated with Drug Response in Alzheimer’s Disease Clinically Meaningful Biomarkers Identified in ANAVEX®2-73 (blarcam
Read more →AVXLAnavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19
NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences to Webcast 2020 Annual Meeting of Shareholders
NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences Announces Publication of Foundational Data for ANAVEX 2-73 (blarcamesine) in Multiple Sclerosis (MS)
Published in Journal of Neuroimmunology, Results Highlight ANAVEX®2-73 (blarcamesine) Shown to Protect and Repair Myelin Forming Cells ANAVEX®2-73 (blarcamesine) Provides optimal Protection of Oligodendroglia against Glutamate Toxicity NEW YORK, Feb. 24, 2020 (GLOBE NEWSWIRE) -
Read more →AVXLAnavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates
NEW YORK, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference
NEW YORK, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX 2-73 (blarcamesine) Clinical Development Program for the Treatment of Rett Syndrome
NEW YORK, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020
NEW YORK, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX 2-73 (blarcamesine) Phase 2 Parkinson’s Disease Dementia (PDD) Clinical Trial
NEW YORK, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Issued New U.S. Patent for ANAVEX 2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrome and Multiple Sclerosis
NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates
NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019
NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Presents ANAVEX 2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Conference
Baseline-matched Real-World external Control Data with Alzheimer’s Disease Neuroimaging Initiative (ADNI): ANAVEX®2-73 (blarcamesine) Cohort showed a Significantly lower Cognitive Decline Compared to the ADNI Control Cohort at Interim 2-Year (104-Week) Timepoint Abundance of Lac
Read more →AVXLAnavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX 2-73 (blarcamesine) for the Treatment of Rett Syndrome
NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Announces Publication of Foundational Data for ANAVEX 2-73 (blarcamesine) in Rett Syndrome
Published in Pharmacology Biochemistry and Behavior, Results Highlight Improvements in Multiple Motor, Sensory, and Autonomic Phenotypes Associated with Rett Syndrome Study Provided Proof-of-Concept for Ongoing ANAVEX®2-73 (blarcamesine) Phase 2 Trials NEW YORK, Nov. 06, 2019 (
Read more →AVXLAnavex Life Sciences Announces ATTENTION-AD ANAVEX 2-73 Extension Clinical Study in Early Alzheimer’s Disease
The ATTENTION-AD extension study will offer the 450 patients enrolled in the on-going Phase 2b/3 ANAVEX®2-73 73 (blarcamesine) Early Alzheimer’s disease study the opportunity to continue their treatment for an additional two years and will provide additional tolerability and effi
Read more →AVXLAnavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX 2-73 for the Treatment of Alzheimer’s Disease
NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX 2-73 Study
NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference
NEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX 2-73 in Patients with Rett Syndrome
Both global efficacy endpoints, RSBQ and CGI-I, showed significant improvement with respect to baseline after 7 weeks of treatment with ANAVEX®2-73 (blarcamesine) ANAVEX®2-73 (blarcamesine) treatment effect was significantly correlated with changes in two different biomarkers li
Read more →AVXLAnavex Life Sciences to Present at the Janney Healthcare Conference 2019
NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX 2-73-RS-003 Clinical Study in Pediatric Patients with Rett Syndrome
NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including
Read more →AVXLAnavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates
NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019
NEW YORK, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX 2-73 in Patients with Rett Syndrome
NEW YORK, July 31, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX 2-73 for the Treatment of Rett Syndrome
NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including A
Read more →AVXLAnavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Response in Patients Treated with ANAVEX 2-73 at 2019 Alzheimer’s Association International Conference (AAIC)
High-Levels of Two Gut Microbiota Families Linked to Improved Responses with ANAVEX®2-73 ANAVEX®2-73 May Have Beneficial Homeostatic Effect on Brain-Gut Microbiota Axis NEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: A
Read more →AVXLAnavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX 2-73 in Patients for Rett Syndrome
NEW YORK, June 25, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX 2-73 for the Treatment of Rett Syndrome (AVATAR)
NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences Reports Fiscal 2019 Second Quarter Financial Results and Provides Clinical Study Updates
Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegener
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2019 Second Quarter Financial Results on Wednesday May 8th, 2019
NEW YORK, May 06, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alz
Read more →AVXLAnavex Life Sciences to Present at the H.C. Wainwright Annual Global Life Sciences Conference
NEW YORK, April 05, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including A
Read more →AVXLAnavex Life Sciences Presents Data On ANAVEX 2-73 in Alzheimer’s Disease at the American Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting
NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including A
Read more →AVXLAnavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX 2-73 for the Treatment of Rett Syndrome in the U.S.
NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including A
Read more →AVXLAnavex Life Sciences to Present at the 31st Annual ROTH Conference 2019
NEW YORK, March 13, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including A
Read more →AVXLAnavex Life Sciences Reaches 50% Enrollment Threshold in ANAVEX 2-73 Parkinson’s Disease Dementia (PDD) Phase 2 Study Ahead of Schedule
NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including A
Read more →AVXLAnavex Life Sciences to Present at the Cowen 39th Annual Health Care Conference 2019
NEW YORK, March 06, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including A
Read more →AVXLAnavex Life Sciences Reports Publication of New Data that Show ANAVEX 2-73 Induces Cellular Recycling Process Linked to the Prevention and Treatment of Age-Associated Diseases
New preclinical data establishes ANAVEX®2-73 as a modulator of autophagy through Sigma-1 receptor activation, possibly needed for the prevention and treatment of neurodegenerative conditions including Alzheimer’s disease, Parkinson’s disease and ALS NEW YORK, March 04, 2019 (GLO
Read more →AVXLAnavex Life Sciences Reports Fiscal 2019 First Quarter Financial Results And Provides Clinical Study Updates
NEW YORK, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences to Present at the 2019 BIO CEO & Investor Conference
NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences to Announce Fiscal 2019 First Quarter Financial Results on Thursday, February 7th, 2019
NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences Announces the Appointment of Walter E Kaufmann, MD as Chief Medical Officer
NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences Reports Fiscal Year 2018 Financial Results And Provides Clinical Study Update
NEW YORK, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences to Announce 2018 Fiscal Year End Financial Results on Wednesday, December 12, 2018
NEW YORK, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences Strengthens its Scientific Advisory Board with Distinguished Researcher for Clinical Treatment of Parkinson’s Disease Dementia (PDD)
NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX 2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Late-Breaking Data Demonstrate Significant Association Between Higher ANAVEX®2-73 Concentration and Maintained Activities of Daily Living and Reduced Cognitive Decline in Alzheimer’s Disease Patients Data Confirm SIGMAR1 and COMT as Genetic Biomarkers of Response to ANAVEX®2-73
Read more →AVXLAnavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX 2-73 in Patients with Rett Syndrome
Study will incorporate genomic precision medicine ANAVEX®2-73-specific biomarkers NEW YORK, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics
Read more →AVXLAnavex Life Sciences to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including A
Read more →AVXLAnavex Life Sciences Reports Fiscal Third Quarter 2018 Financial Results
Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegene
Read more →AVXLAnavex Life Sciences to Announce Fiscal Third Quarter 2018 Financial Results on Thursday, August 9, 2018
Conference Call and Webcast To be Held Thursday, August 9, 2018 at 4:30pm Eastern time NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp., (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therape
Read more →AVXLAnavex Life Sciences Presents New Data Identifying Treatment Response Biomarkers in Alzheimer’s Disease Patients Treated with Investigational ANAVEX 2-73 at 2018 Alzheimer’s Association International Conference (AAIC)
An Analysis of More Than 33,000 Genes Identified Variants That May Enable a Precision Medicine Approach to Alzheimer’s Disease Research and Treatment The Study Identified 80 Percent of Participants as ANAVEX®2-73 Responders Resulting in Improved Cognition (MMSE) and Activities o
Read more →AVXLAnavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ANAVEX 2-73 for the Treatment of Parkinson’s Disease Dementia
Primary Endpoint Cognition with Secondary Endpoints Parkinsonian Motor Symptoms and Sleep Function during 14-Week Study NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company de
Read more →AVXLAnavex Life Sciences Receives Approval To Initiate Phase 2b/3 Clinical Trial of ANAVEX 2-73 for the Treatment of Early Alzheimer’s Disease
ANAVEX®2-73 Being Studied as Potential First Precision Medicine Biomarker-guided, Targeted Therapeutic in Alzheimer’s Disease Primary and Secondary Endpoints measuring Safety, and Cognitive and Functional Efficacy (ADAS-Cog, ADCS-ADL and CDR-SB) NEW YORK, July 03, 2018 (GLOBE N
Read more →AVXLAnavex Life Sciences Reports Fiscal Second Quarter 2018 Financial Results
Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK, May 10, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenera
Read more →AVXLAnavex Life Sciences to Announce Fiscal Second Quarter 2018 Financial Results on Thursday, May 10, 2018
Conference Call and Webcast To be Held Thursday, May 10, 2018 at 4:30pm Eastern Time NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp., (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutic
Read more →AVXLAnavex Life Sciences to Initiate Phase 2 Study of ANAVEX 2-73 in Parkinson’s Disease Dementia and Provides Clinical Study Update for ANAVEX 2-73 in Rett Syndrome
NEW YORK, April 17, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences to Present at the 30th Annual ROTH Conference
NEW YORK, March 09, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)
ANAVEX®2-73 Extends Survival and Reduces Seizures in an Orphan Disease Model NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for
Read more →AVXLAnavex Life Sciences to Present at Cowen and Company 38th Annual Health Care Conference
NEW YORK , March 06, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including A
Read more →AVXLAnavex Life Sciences Strengthens Management Team and Board of Directors Company Appoints Stephan Toutain as Senior Vice President of Operations and Claus van der Velden to Board of Directors New York
Anavex Life Sciences Strengthens Management Team and Board of Directors Company Appoints Stephan Toutain as Senior Vice President of Operations and Claus van der Velden to Board of Directors 2018 - Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clini
Read more →AVXLAnavex Life Sciences to Present at the 2018 BIO CEO & Investor Conference
NEW YORK, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alz
Read more →AVXLAnavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial Results
Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegen
Read more →AVXLAnavex Life Sciences to Announce Fiscal First Quarter 2018 Financial Results and Provide an Update on Clinical Programs and Corporate Highlights on Wednesday, February 7, 2018
Conference Call and Webcast to be Held Wednesday, February 7, 2018 at 4:30pm Eastern Time NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp., (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated thera
Read more →AVXLAnavex Life Sciences to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alz
Read more →AVXLAnavex Life Sciences Reports Potential Normalization of Hypertension with ANAVEX 2-73 Published in The Journal of Clinical Hypertension
NEW YORK, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases today reports
Read more →AVXLAnavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs
Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegener
Read more →AVXLAnavex Life Sciences Reports Newly Published Data on Alzheimer's Disease Research Demonstrate the Neuroprotective Features of the Sigma-1 Receptor
Anavex’ Sigma-1 Receptor Agonists Protect Mitochondrial Function from Amyloid Toxicity and Absence of Sigma-1 Receptor Function Exacerbates Amyloid Toxicity NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) -- New data published in the current issue of the peer-reviewed scientific journa
Read more →AVXLAnavex Life Sciences to Present at the 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable in Washington, DC
NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheim
Read more →AVXLAnavex Life Sciences Presents New Clinical Data of Investigational Alzheimer’s Disease Treatment ANAVEX 2-73 at 2017 Clinical Trials on Alzheimer’s Disease Meeting
Presentation Includes New Data from Phase 2a Long-Term Extension Cohort NEW YORK, Nov. 04, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatme
Read more →AVXLAnavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation’s Parkinson's Disease Therapeutics Conference
ANAVEX®2-73 Shown to have Neurorestorative Effects in a Model for Experimental Parkinsonism NEW YORK, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeu
Read more →AVXLAnavex Life Sciences Announces New Data Related to Multiple Sclerosis Presented at 7th ECTRIMS-ACTRIMS Meeting MSPARIS2017
ANAVEX®2-73 Shown to Protect and Repair Myelin Forming Cells NEW YORK, Oct. 27, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neuro
Read more →AVXLAnavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX 2-73 in Mild-to-Moderate Alzheimer’s Disease Patients; Conference call today at 8:30am ET
ANAVEX2-73 demonstrates desirable PK/PD properties, describing the relationship between drug concentration and the effect observed Anavex is incorporating advanced Artificial Intelligence platform for the analysis of Phase 2a results with the aim to increase the chances of succe
Read more →AVXLAnavex Life Sciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference
NEW YORK, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Nasdaq:AVXL), a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other cen
Read more →AVXLAnavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX™ 2-73
NEW YORK, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL) today announced that the United States Patent and Trademark Office has issued U.S. Patent Number 9,750,746 entitled “ANAVEX 2-73 and certain anticholinesterase inhibi
Read more →AVXLAnavex Reports Fiscal Third Quarter 2017 Financial Results
NEW YORK, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alz
Read more →AVXLAnavex Life Sciences Appoints Distinguished Researcher in Neurology and Epilepsy to Scientific Advisory Board
NEW YORK, July 20, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alz
Read more →AVXLAnavex Life Sciences to Present at Jefferies 2017 Global Healthcare Conference
NEW YORK, June 05, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alz
Read more →AVXLAnavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome: Data Presented at Antiepileptic Drug Trials XIV 2017 Conference
NEW YORK, May 22, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzh
Read more →AVXLAnavex Reports Fiscal Second Quarter 2017 Financial Results
NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzh
Read more →AVXLAnavex Life Sciences Appoints Former FDA Officer as Senior Vice President of Regulatory Affairs
NEW YORK, May 01, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzh
Read more →AVXLAnavex Life Sciences Reports New Mechanism of Action Data Related to ANAVEX Compounds Targeting Sigma-1 Receptor
NEW YORK, April 03, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences Reports Dismissal of Appeal in the Cortina Lawsuit
NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences to Present at the 13th International Conference on Alzheimer's and Parkinson's Diseases AD/PD™ 2017
NEW YORK, March 29, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences to Present at Oppenheimer 27th Annual Healthcare Conference
NEW YORK, March 15, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences to Present at 14th Annual BIO Asia International Conference
NEW YORK, March 13, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences Strengthens Board of Directors
Anavex Life Sciences Strengthens Board of NEW YORK - February 13, 2017 - Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodev
Read more →AVXLAnavex Life Sciences’ CEO Joins BIO CEO & Investor Conference 2017 Panel “Designing Clinical Trials in 21st Century Cures Paradigm”
NEW YORK, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alz
Read more →AVXLAnavex Reports Fiscal First Quarter 2017 Financial Results
NEW YORK, Feb. 07, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alz
Read more →AVXLAnavex Life Sciences to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference
NEW YORK, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alz
Read more →AVXLAnavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017
ANAVEX 2-73 has U.S. FDA Orphan Drug Designation for Rett Syndrome NEW YORK and CINCINNATI, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Nasdaq:AVXL) and the International Rett Syndrome Foundation, doing business as Rettsyndrome.org today announced that Rettsynd
Read more →AVXLAnavex Life Sciences Obtains Permanent Dismissal of All Claims in Securities Lawsuit
NEW YORK, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Nasdaq:AVXL) a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other centr
Read more →AVXLAnavex Life Sciences Reports Fiscal 2016 Financial Results - Conference Call and Webcast Today at 4:30 p.m. ET to Discuss Financial Results and Clinical Progress
NEW YORK, Dec. 12, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alz
Read more →AVXLAnavex Life Sciences Announces 12-Month Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease Patients
Data presentation at CTAD 2016 NEW YORK, Dec. 08, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL) today announced a positive 57-week update from its Phase 2a study in mild-to-moderate Alzheimer’s disease (AD) patients for ANAVEX 2-73
Read more →AVXLAnavex Life Sciences to Present at Annual Mental Health Parity Addiction Equity Act Roundtable at U.S. Capitol, Washington, DC
NEW YORK, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL) today announced that Christopher U. Missling, Ph.D., President and Chief Executive Officer, will participate on a panel comprising 14 representatives from government a
Read more →AVXLAnavex Life Sciences Appoints Three Distinguished Researchers To Scientific Advisory Board
NEW YORK, Nov. 28, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alz
Read more →AVXLAnavex Life Sciences Announces Data on 41-Week Treatment of ANAVEX 2-73 for Patients with Alzheimer’s Disease − Investigational Treatment suggests to curb Cognitive and Functional Decline
NEW YORK, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL) today announced a positive 41-week update from its Phase 2a study in mild-to-moderate Alzheimer’s disease (AD) patients for ANAVEX 2-73, which targets cellular homeost
Read more →AVXLAnavex Life Sciences Novel Sigma-1 / Sigma-2 Ligand Shows Encouraging Results as an Analgesic in Animal Models of Neuropathic and Visceral Pain
NEW YORK, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL) today reported encouraging preclinical efficacy for the treatment of neuropathic pain and visceral pain with their novel compound, ANAVEX 1066. The poster titled “Mixe
Read more →AVXLChristopher U. Missling, MS, PhD, MBA, President and CEO of Anavex Life Sciences Corp. Dr. Missling, President and CEO of Anavex, has over 20 years of healthcare industry experience within large pharmaceutical companies,
Christopher U. Missling, MS, PhD, MBA, President and CEO of Anavex Life Sciences Corp. Dr. Missling, President and CEO of Anavex, has over 20 years of healthcare industry experience within large pharmaceutical companies, the biotech industry and investment banking. Prior to j
Read more →AVXLAnavex Life Sciences and Ariana Pharma Collaborate to Accelerate Timelines and Improve Efficiency of Alzheimer’s and Parkinson’s Clinical Development Programs
NEW YORK, Oct. 05, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alz
Read more →AVXLAnavex Compound to be Tested in Biogen Neurological Protection Model
NEW YORK, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Life Sciences’ Drug Shows Efficacy to Support Potential Disease Modification in Parkinson’s Disease
NEW YORK, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL) today presented preclinical data demonstrating that ANAVEX 2-73, a sigma-1 receptor agonist, restores function in a classic animal model of Parkinson’s disease. Signi
Read more →AVXLAnavex to Present at Ladenburg Thalmann 2016 Healthcare Conference
NEW YORK, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex to Participate in Mizuho Therapeutics Conference
NEW YORK, Sept. 14, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Al
Read more →AVXLAnavex Reports Fiscal Third Quarter 2016 Financial Results
NEW YORK, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alz
Read more →AVXLAnavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients Presented at AAIC 2016
NEW YORK, July 29, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), confirms the information in the July 27, 2016 press release announcing positive results from the Phase 2a Alzheimer’s trial for ANAVEX 2-73. Dr. Norman Relkin, MD, P
Read more →AVXLAnavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016
Sustained Response Through 31 Weeks for both Cognitive (MMSE) and Functional (ADCS-ADL) Measures NEW YORK, July 27, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated
Read more →AVXLAnavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016
Results Feature Favorable Safety, Maximum Tolerated Dose, Positive Dose Response as well as Positive Unexpected Therapeutic Response Events NEW YORK, July 24, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharm
Read more →AVXLAnavex to Present at the Alzheimer’s Association International Conference (AAIC) 2016
NEW YORK, July 12, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alz
Read more →AVXLAnavex to Present at the 2016 Rett Syndrome Symposium
NEW YORK, June 23, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL) a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzh
Read more →AVXLAnavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms
NEW YORK, June 22, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alz
Read more →AVXLAnavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X – Autism-Related Disorders
NEW YORK, June 06, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alz
Read more →AVXLAnavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 for the Treatment of Rett Syndrome
NEW YORK, May 20, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzh
Read more →AVXLAnavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms
NEW YORK, May 18, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzh
Read more →AVXLAnavex Reports Fiscal Second Quarter 2016 Financial Results
NEW YORK, May 11, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzh
Read more →AVXLAnavex Presents New Data on Preclinical Development of ANAVEX 3-71
NEW YORK, March 14, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, othe
Read more →AVXLAnavex Announces Two-Year Clinical Extension Study of ANAVEX 2-73 and Presents Phase 2a Dose-Response Analysis at AAT Conference
NEW YORK, March 10, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL) today announced that the Company has received the approval from the Ethics Committee in Australia to extend the ongoing Phase 2a Alzheimer’s trial, which had been req
Read more →AVXLAnavex Presents Preclinical Results of ANAVEX 2-73 in Rett Syndrome
- Data presentation at 2016 Epilepsy Pipeline Conference - - Company exploring potential to advance ANAVEX 2-73 into human clinical studies in rare disease indication - NEW YORK, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AV
Read more →AVXLANAVEX 2-73 Preclinical Data in New Indication to be Presented at ACTRIMS 2016
NEW YORK, Feb. 17, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other cen
Read more →AVXLAnavex Reports Fiscal First Quarter 2016 Financial Results
NEW YORK, Feb. 08, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other
Read more →AVXLAnavex to Present at 18th Annual BIO CEO & Investor Conference on February 9th 2016
NEW YORK, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other
Read more →AVXLAnavex Announces Positive Dose-Response Data for ANAVEX 2-73 in Alzheimer's Disease Patients
NEW YORK, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other
Read more →AVXLAnavex Issues Statement Addressing Recent Press Releases by Law Firms
NEW YORK, Jan. 08, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other
Read more →AVXLAnavex Announces Fiscal 2015 Year-End Financial Results
NEW YORK, Dec. 29, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other
Read more →AVXLAnavex to Present at Third Annual MHPAEA Business Roundtable in Washington, D.C.
NEW YORK, Dec. 07, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various type
Read more →AVXLAnavex Expands Management Team
NEW YORK, Dec. 02, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various type
Read more →AVXLAnavex Announces Executive Overseeing Regulatory Affairs
NEW YORK, Nov. 25, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various type
Read more →AVXLAnavex to Present at American Epilepsy Society Annual Meeting ANAVEX 2-73 Demonstrates Anti-Seizure Effects in Well Established Preclinical Seizure Models
NEW YORK, Nov. 19, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various type
Read more →AVXLAnavex Announces Preparation of Regulatory Filings Based on Guidance From the FDA
NEW YORK, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various type
Read more →AVXLAnavex Confirms Data for Phase 2a Alzheimer’s Trial for ANAVEX 2-73
NEW YORK, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL) confirms the information in the November 9, 2015 press release announcing positive safety and cognitive efficacy data from the Phase 2a Alzheimer’s trial for ANAVEX 2-
Read more →AVXLAnavex Announces Positive Primary and Secondary Endpoints Were Achieved in a Phase 2a Clinical Trial of ANAVEX 2-73 in Alzheimer’s Disease
NEW YORK, Nov. 09, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL). On Saturday, investigators presented positive safety and cognitive efficacy data for ANAVEX 2-73, the Company’s lead investigational oral treatment for Alzheimer’s di
Read more →AVXLAnavex Announces CTAD 2015 Abstract
NEW YORK, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various typ
Read more →AVXLAnavex Life Sciences Corp. (Nasdaq:AVXL) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Nasdaq:AVXL), a clinical-stage biopharmaceutical company that is developing drug candidates for Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, will visit
Read more →AVXLAnavex Commences Trading on NASDAQ Today – To Ring Friday’s Closing Bell
NEW YORK, Oct. 28, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various type
Read more →AVXLAnavex Announces Uplisting to NASDAQ
NEW YORK, Oct. 26, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of ca
Read more →AVXLAnavex to Present at 4th Annual OktoberINVESTfest Conference
NEW YORK, Oct. 12, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 4th annual OktoberINVESTfest investors conference on Tuesd
Read more →AVXLAnavex to Present Interim Phase 2a Clinical Trial Data of ANAVEX 2-73 at Late-Breaking Oral Session of CTAD 2015 Conference
NEW YORK, Oct. 07, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various type
Read more →AVXLAnavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock Split
NEW YORK, Oct. 06, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various type
Read more →AVXLFiled by newsfilecorp.com Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock Split
Anavex Prepares for Uplisting to NASDAQ, Announces Reverse NEW YORK, NY October 6, 2015 Anavex Life Sciences Corp. ( Anavex or the Company ) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer s disease, other central nervou
Read more →AVXLAnavex Completes Patient Enrollment for Phase 2a Alzheimer’s Trial Ahead of Schedule
NEW YORK, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various typ
Read more →AVXLAnavex to Present at 2015 Ladenburg Thalmann Healthcare Conference
NEW YORK, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various typ
Read more →AVXLAnavex Appoints International Alzheimer’s Expert to Scientific Advisory Board
NEW YORK, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various typ
Read more →AVXLFiled by newsfilecorp.com
ANAVEX LIFE SCIENCES CORP. CONSOLIDATED BALANCE SHEETS September 15, 2015 and September 30, September 15, September 30, 2015 2014 Current Cash $ 13,101,846 $ 7,262,138 Prepaid expenses 79,321 89,117 Total current assets 13,181,167 7,351,255 Equipment
Read more →AVXLAnavex Reports Fiscal Third Quarter 2015 Financial Results
NEW YORK, Aug. 17, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various type
Read more →AVXLAnavex Receives Notice of Allowance for U.S. Patent Application Related to ANAVEX 2-73
NEW YORK, Aug. 12, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various type
Read more →AVXLAnavex Awarded Grant From The Michael J. Fox Foundation for Parkinson’s Research
NEW YORK, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various type
Read more →AVXLAnavex Presents Positive Initial Phase 2a Study Data With ANAVEX 2-73 Showing Early Evidence of Improving Cognition in Patients With Alzheimer’s Disease at AAIC 2015
NEW YORK, July 22, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL) today announced initial positive cognitive data for ANAVEX 2-73, the Company’s lead investigational oral treatment for Alzheimer’s targeting sigma-1 and muscarinic rece
Read more →AVXLAnavex to Present Initial Clinical Data From the Phase 2a Clinical Trial of ANAVEX 2-73 at the Alzheimer’s Association International Conference (AAIC)
NEW YORK, June 30, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL) a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types
Read more →AVXLAnavex Strengthens Board of Directors
NEW YORK, June 18, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various type
Read more →AVXLFiled by newsfilecorp.com ANAVEX LIFE SCIENCES CORP. CONSOLIDATED BALANCE SHEETS ASSETS May 8
ANAVEX LIFE SCIENCES CORP. CONSOLIDATED BALANCE ASSETS May 8, September 30, 2015 2014 Current Cash $ 6,746,263 $ 7,262,138 Prepaid expenses 31,445 89,117 Total current assets 6,777,708 7,351,255 Equipment 1,749 2,247 Total assets $ 6,779,457 $ 7,
Read more →AVXLAnavex Encouraged by Data Showing Sigma-1 Receptor Reduces Tau Dysfunction, a Hallmark of Alzheimer's Disease
NEW YORK, May 21, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types
Read more →AVXLAnavex Releases Promising Full Preclinical Epilepsy Data at Antiepileptic Drug Trials XIII Conference
NEW YORK, May 18, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types
Read more →AVXLAnavex Reports Fiscal Second Quarter 2015 Financial Results
NEW YORK, May 15, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types
Read more →AVXLAnavex to Present at 2015 Marcum Conference on May 27th
NEW YORK, May 13, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 2015 Marcum Microcap Conference on Wednesday, May 27, 2015
Read more →AVXLAnavex to Present on Sigma-1 Receptors at the World Orphan Drug Congress and to Reveal New Epilepsy Data at Antiepileptic Drug Trials XIII Conference
NEW YORK, April 23, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the World Orphan Drug Congress on Thursday, April 23, 2015 a
Read more →AVXLAnavex Encouraged by New Scientific Data Revealing Positive Role of Sigma-1 Receptors in Brain Injuries
NEW YORK, April 7, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL) is encouraged by the findings of a new report in the latest issue of peer-reviewed scientific journal Neuroscience Letters. The study demonstrates for the first time th
Read more →AVXLAnavex Presents Positive Results for Both ANAVEX 2-73 and ANAVEX 3-71 in Alzheimer's Models at 2015 AD/PD(TM) Conference
ANAVEX 2-73 strong reversal of memory impairment in Alzheimer's disease model ANAVEX 3-71 strong reversal of synaptic loss in Alzheimer's disease models NEW YORK, March 23, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL), a clinical-
Read more →AVXLAnavex to Participate in Phase 3 Clinical Trials Panel at AD/PD 2015
NEW YORK, March 17, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's and other central nervous system (CNS) diseases, pain and various types of
Read more →AVXLAnavex Appoints Epilepsy and Clinical Trial Methodology Expert to Scientific Advisory Board
NEW YORK, March 12, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various type
Read more →AVXLAnavex to Present at Sigma-1 Receptors Symposium
NEW YORK, March 10, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL) a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types
Read more →AVXLAnavex Appoints Scientific Advisory Board Member With Expertise in Protein Misfolding Neurodegenerative Diseases
NEW YORK, March 5, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types
Read more →AVXLAnavex to Present at 27th Annual ROTH Conference on March 11th
NEW YORK, March 3, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 27th Annual ROTH Conference on Wednesday, March 11, 2015 a
Read more →AVXLANAVEX 2-73 Could Prevent Alzheimer's Disease in Addition to Modifying and Treating Symptoms
NEW YORK, Feb. 25, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX: AVXL) is encouraged by the findings of a research report in the current issue of peer-reviewed scientific journal Frontiers in Cellular Neuroscience. Among its conclusions,
Read more →AVXLAnavex Reports Fiscal First Quarter 2015 Financial Results
NEW YORK, Feb. 18, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types
Read more →AVXLAnavex Confirms Positive Preclinical Epilepsy Data for ANAVEX 2-73 - Validation as Potential Platform Drug for Multiple Neurodegenerative Diseases
NEW YORK, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL) today confirmed positive preclinical data for its lead drug candidate ANAVEX 2-73 for the potential treatment of epilepsy, validating it also as a prospective platform d
Read more →AVXLAnavex to Present at 17th Annual BIO CEO & Investor Conference on February 10th
NEW YORK, Feb. 4, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 17th Annual BIO CEO & Investor Conference on Tuesday, Febru
Read more →AVXLAnavex Doses First Alzheimer's Patient in Phase 2a Trial of ANAVEX 2-73 and ANAVEX PLUS
NEW YORK, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL) today announced dosing of the first patient in the Phase 2a clinical trial of ANAVEX 2-73 and ANAVEX PLUS, which are being developed as an oral therapy and oral drug co
Read more →AVXLAnavex Announces Panel Discussion and Presention at OneMedForum Conference
NEW YORK, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL), a clinical stage biopharmaceutical company currently in a Phase2a clinical trial for Alzheimer's disease, today announced that Christopher U. Missling, PhD, President a
Read more →AVXLAnavex Encouraged by Scientific Data Confirming Sigma-1 Receptor's Beneficial Direct Interaction With Cannabinoid Receptor
NEW YORK, Jan. 6, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL) welcomes new data published in the current issue of the International Journal of Neuropsychopharmacology (IJNP) revealing that the sigma-1 receptor, the Company's drug t
Read more →AVXLAnavex Announces Fiscal 2014 Fourth Quarter and Year-End Financial Results
NEW YORK, Dec. 30, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and variou
Read more →AVXLAnavex to Present at Biotech Showcase 2015 in San Francisco
NEW YORK, Dec. 18, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and variou
Read more →AVXLAnavex Begins Enrollment of Alzheimer's Patients in Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS
NEW YORK, Dec. 16, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL) today announced enrollment of the first patient in a multicenter Phase 2a clinical trial for ANAVEX 2-73, which is being evaluated for the treatment of Alzheimer's dise
Read more →AVXLFiled by newsfilecorp.com Anavex Upgrades to OTCQX Marketplace NEW YORK, NY, December XX, 2014 Anavex Life Sciences Corp . ( Anavex or the Company ) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing no
Anavex Upgrades to OTCQX Marketplace NEW YORK, NY, December XX, 2014 Anavex Life Sciences Corp. ( Anavex or the Company ) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer s disease, other diseases of the central ner
Read more →AVXLAnavex Upgrades to OTCQX Marketplace
NEW YORK, Dec. 12, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and variou
Read more →AVXLAnavex Announces Positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for the Treatment of Alzheimer's
NEW YORK, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL) announced full data results from the Phase 1 clinical trial of ANAVEX 2-73, the Company's lead investigational oral treatment for Alzheimer's, which has shown potential
Read more →AVXLAnavex to Present Full Phase 1 Clinical Trial Data for ANAVEX 2-73 at CNS Summit 2014 Conference
NEW YORK, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS), and vario
Read more →AVXLAnavex to Present at SeeThruEquity Investor Conference in New York City
NEW YORK, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various
Read more →AVXLAnavex Receives Regulatory Approval to Initiate Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS for Alzheimer's Disease
NEW YORK, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL) announced today that it has received regulatory approval from the Ethics Committee in Australia to initiate a Phase 2a clinical trial of its proprietary compound, ANAVEX
Read more →AVXLAnavex Supports Alzheimer's Foundation of America's 3rd Annual Concepts in Care Educational Conference
NEW YORK, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and variou
Read more →AVXLAnavex to Present at Rodman & Renshaw 16th Annual Global Investment Conference
NEW YORK, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and variou
Read more →AVXLAnavex Selects The Alfred Hospital in Melbourne, Australia as Lead Site for Phase 2a Alzheimer's Clinical Trial
NEW YORK, Aug. 26, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and variou
Read more →AVXLAnavex Reports That Antidepressant Fluvoxamine Reduces Stress Through Sigma-1 Receptor
NEW YORK, Aug. 19, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and variou
Read more →AVXLAnavex Reports Fiscal Third Quarter 2014 Financial Results
NEW YORK, Aug. 13, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and variou
Read more →AVXLAnavex Appoints Experienced Pharma Executive as Vice President of Clinical Operations
NEW YORK, Aug. 7, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and variou
Read more →AVXLAnavex Achieves Key Milestone as it Secures cGMP Manufacturing for Drug Candidate Trial Supplies
NEW YORK, July 21, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and variou
Read more →AVXLANAVEX 3-71 Highly Effective and Disease-Modifying Against All Major Alzheimer's Hallmarks in Preclinical Disease Model
NEW YORK, July 14, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and variou
Read more →AVXLAnavex Announces Report Expanding Opportunity for Therapeutic Application of Anavex Compounds
NEW YORK, June 30, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and variou
Read more →AVXLAnavex Awarded New U.S. Patent
NEW YORK, June 4, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various
Read more →AVXLAnavex Appoints Dr. Abraham Fisher to Scientific Advisory Board
NEW YORK, May 28, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various
Read more →AVXLAnavex Reports That New Data Confirms Calcium Target Over-Expression May be Involved in Causing Alzheimer's Disease
NEW YORK, May 22, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various
Read more →AVXLAnavex Provides Business Update Including Clinical Trial Plans for ANAVEX PLUS in Alzheimer's Disease
NEW YORK, May 15, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various
Read more →AVXLAnavex Strengthens Scientific Advisory Board With Clinical Trial Expert
NEW YORK, May 12, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various
Read more →AVXLAnavex Appoints Senior Healthcare and Pharmaceutical Executives to Board of Directors
NEW YORK, May 8, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various
Read more →AVXLFiled by newsfilecorp.com Anavex Appoints Senior Healthcare and Pharmaceutical Executives to Board of Directors NEW YORK (
Anavex Appoints Senior Healthcare and Pharmaceutical Executives to Board of Directors NEW YORK (May 8, 2014) Anavex Life Sciences Corp. ( Anavex or the Company ) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's di
Read more →AVXLAnavex Encouraged by Scientific Data Confirming Sigma-1 Receptor Agonist is Potentially Disease-Modifying in Parkinson's Disease
NEW YORK, April 29, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, other diseases of the central nervous system (CNS) and various types
Read more →AVXLAnavex Strengthens Alzheimer's Pipeline, Obtains Exclusive Worldwide Rights to Intellectual Property
NEW YORK, March 31, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of ca
Read more →AVXLAnavex Reports Predicted Clinical Effect of Both ANAVEX 2-73 and ANAVEX PLUS in a Humanized Cortical Cognitive Model for Alzheimer's Disease
NEW YORK, March 27, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of ca
Read more →AVXLAnavex Successfully Closes $10 Million Financing to Initiate Phase 1b/2a Alzheimer's Clinical Trial
NEW YORK, March 19, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of ca
Read more →AVXLAnavex Announces $10 Million Private Placement of Convertible Debentures
NEW YORK, March 13, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of ca
Read more →AVXLFiled by newsfilecorp.com Anavex Announces $10 Million Private Placement of Convertible Debentures Secures Capital to Execute Clinical Trial Phase 1b/2a in Alzheimer s Disease and Advance Product Portfolio New York, NY
Anavex Announces $10 Million Private Placement of Convertible Secures Capital to Execute Clinical Trial Phase 1b/2a in Alzheimer s Disease and Advance Product Portfolio New York, NY March 13, 2014 - Anavex Life Sciences Corp. ( Anavex or the Company ) (OTCQB: AVXL), a clinica
Read more →AVXLAnavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS (Lou Gehrig's Disease)
NEW YORK, March 10, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of ca
Read more →AVXLAnavex: Research Report Reveals Cardioprotective Action of Sigma-1 Receptor Agonists
NEW YORK, March 4, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL) is encouraged by the findings of a research report published in the current issue of peer-reviewed scientific journal Life Sciences. Among its conclusions, the report r
Read more →AVXLAnavex to Present at 16th Annual BIO CEO & Investor Conference
NEW YORK, Feb. 3, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will be presenting at the 16th Annual BIO CEO & Investor Conference on Monday,
Read more →AVXLAnavex Agreement With The Roskamp Institute to Advance the Clinical Development of ANAVEX PLUS
NEW YORK, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL) today announced that they have established an agreement with The Roskamp Institute for the clinical development of ANAVEX PLUS, a new combination drug of ANAVEX 2-73 an
Read more →AVXLAnavex CEO Invited to Present at Upcoming Investment Conferences
NEW YORK, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL) today announced that its President and Chief Executive Officer Christopher U. Missling, PhD, will participate in the 7th Annual OneMedForum: Investing in Healthcare 2014
Read more →AVXLAnavex Appoints Clinical Design Expert to Scientific Advisory Board
NEW YORK, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL) today announced the appointment of John Harrison, PhD, to its Scientific Advisory Board. Dr. Harrison is an internationally acknowledged specialist for design of human
Read more →AVXLFiled by newsfilecorp.com Safe Harbor This presentation contains forward -looking statements made within the meaning of the Private Securities Litigation Reform Act of 1995 by Anavex Life Sciences Corp. and its represent
This presentation contains forward -looking statements made within the meaning of the Private Securities Litigation Reform Act of 1995 by Anavex Life Sciences Corp. and its representatives. These statements can be identified by introductory words such as ``expects,'' ``plans,
Read more →AVXLFiled by newsfilecorp.com Anavex raises $2.6 -million in private placement and conversion of liabilities, enters into $10-million financing commitment and appoints CEO New York, NY
Anavex raises $2.6 -million in private placement and conversion of liabilities, enters into $10-million financing commitment New York, NY July 8, 2013 -- Anavex Life Sciences Corp. ( Anavex or the Company ) (OTCQB: AVXL) today announced the closing of $2.6 -million in a priv
Read more →AVXLFiled by newsfilecorp.com Anavex appoints Tom Skarpelos as Director Vancouver, BC
Anavex appoints Tom Skarpelos as Director Vancouver, BC January 9, 2013 -- Anavex Life Sciences Corp. ( Anavex ) (OTCQB: AVXL) announces the appointment of Athanasios (Tom) Skarpelos as a Director of the company effective January 9, 2013. Tom has been actively involved in Ana
Read more →AVXLFiled by newsfilecorp.com Anavex appoints Robert Chisholm as CFO Vancouver, BC
Anavex appoints Robert Chisholm as CFO Vancouver, BC -- June 26, 2012 -- Anavex Life Sciences Corp. ( Anavex ) (OTCBB: AVXL) today announced the appointment of Robert Chisholm as Chief Financial Officer ( CFO ) of the company effective June 26, 2012. Mr. Chisholm will remain
Read more →AVXLFiled by newsfilecorp.com Anavex announces director resignation Palo Alto, CA
Anavex announces director resignation Palo Alto, CA -- March 27, 2012 -- Anavex Life Sciences Corp. ( Anavex ) (OTCBB: AVXL) reports the departure of Dr. George Tidmarsh as executive director. Dr. Tidmarsh resigned to devote time to other professional responsibilities. Anavex
Read more →AVXLFiled by newsfilecorp.com ANAVEX CLOSES PRIVATE PLACEMENT Portola Valley, CA
ANAVEX CLOSES PRIVATE PLACEMENT Portola Valley, CA February 10, 2012 -- Anavex Life Sciences Corp. ( Anavex ) (OTCBB: AVXL) today announced the closing of a private placement of 270,000 units of the company to three investors at a price of US$1.25 per unit, for gross proceeds
Read more →AVXLFiled by newsfilecorp.com ANAVEX CLOSES PRIVATE PLACEMENT Hoboken, NJ
ANAVEX CLOSES PRIVATE PLACEMENT Hoboken, NJ December 7, 2011 -- Anavex Life Sciences Corp. ( Anavex ) (OTCBB: AVXL) today announced the closing of a private placement of 615,600 units to two investors at a price of US$1.25 per unit for gross proceeds of US$769,500. Each unit
Read more →AVXLFiled by newsfilecorp.com Anavex successfully completes a Phase 1 clinical trial for ANAVEX 2-73 Hoboken, NJ
Anavex successfully completes a Phase 1 clinical trial for Hoboken, NJ November 14, 2011 -- Anavex Life Sciences Corp. ( Anavex ) (OTCBB: AVXL) today announced the successful completion of its Phase 1 single ascending dose (SAD) clinical trial of ANAVEX 2-73, the company s le
Read more →AVXLANAVEX ANNOUNCES RESIGNATION OF DIRECTOR Hoboken, NJ - October 21 , 2011 -- Anavex Life Sciences Corp. (the "Company" or "Anavex") (OTCBB: AVXL) today announced that Alison Ayers has resigned as a director of the Company
ANAVEX ANNOUNCES RESIGNATION OF DIRECTOR Hoboken, NJ - October 21, 2011 -- Anavex Life Sciences Corp. (the "Company" or "Anavex") (OTCBB: AVXL) today announced that Alison Ayers has resigned as a director of the Company effective immediately. Ms. Ayers has taken on new employmen
Read more →AVXLFiled by newsfilecorp.com Anavex appoints Dr. George Tidmarsh as Executive Director Hoboken, NJ
Anavex appoints Dr. George Tidmarsh as Executive Hoboken, NJ October 12, 2011 -- Anavex Life Sciences Corp. ( Anavex ) (OTCBB: AVXL) today announced the appointment of Dr. George Tidmarsh as director, and his engagement to act as an executive director. Dr. Tidmarsh is an exec
Read more →AVXLFiled by newsfilecorp.com Anavex announces director resignation Hoboken, NJ
Anavex announces director resignation Hoboken, NJ September 16, 2011 -- Anavex Life Sciences Corp. ( Anavex ) reports that Dr. Cameron Durrant has resigned as Director and Executive Chairman of the Board effective immediately. Anavex s Board of Directors would like to thank D
Read more →AVXLFiled by newsfilecorp.com Anavex rapidly advances ANAVEX 2-73 for Alzheimer s disease, Phase I clinical trial progressing well Hoboken, NJ
Anavex rapidly advances ANAVEX 2-73 for Alzheimer s disease, Phase I clinical trial progressing well Hoboken, NJ July 6, 2011 -- Anavex Life Sciences Corp. ( Anavex ) (OTCBB: AVXL) has commenced the 30 mg dose step in its ongoing Phase I clinical trial to evaluate ANAVEX 2-73
Read more →AVXLFiled by newsfilecorp.com ANAVEX APPOINTS ROBERT CHISHOLM TO BOARD OF DIRECTORS Hoboken, NJ
ANAVEX APPOINTS ROBERT CHISHOLM TO BOARD OF DIRECTORS Hoboken, NJ May 13, 2011 -- Anavex Life Sciences Corp. ( Anavex ) (OTCBB: AVXL) today announced the appointment of Robert Chisholm to the Board of Directors. As a finance and administration executive with more than 25 year
Read more →AVXLFiled by newsfilecorp.com ANAVEX ARRANGES FOR CONVERTIBLE DEBENTURE Hoboken, NJ
ANAVEX ARRANGES FOR CONVERTIBLE DEBENTURE Hoboken, NJ May 6, 2011 -- Anavex Life Sciences Corp. (the Company or Anavex ) (OTCBB: AVXL) today announced that the Company has arranged for the sale of $1,000,000 of convertible debentures to one investor in On April 20, 2011, Anav
Read more →AVXLFiled by newsfilecorp.com ANAVEX: FIRST-IN-HUMAN DOSING COMMENCED IN ANAVEX 2-73 CLINICAL TRIAL FOR ALZHEIMER S DISEASE Hoboken, NJ
ANAVEX: FIRST-IN-HUMAN DOSING COMMENCED IN ANAVEX 2-73 TRIAL FOR ALZHEIMER S DISEASE Hoboken, NJ April 20, 2011 -- Anavex Life Sciences Corp. ( Anavex ) (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical tri
Read more →AVXLANAVEX ARRANGES FOR CONVERTIBLE DEBENTURE Hoboken, NJ - May 9 , 2011 -- Anavex Life Sciences Corp. (the "Company" or "Anavex") (OTCBB: AVXL) today announced that the Company has arranged for the sale of up to $1,000,000
ANAVEX ARRANGES FOR CONVERTIBLE DEBENTURE Hoboken, NJ - May 9, 2011 -- Anavex Life Sciences Corp. (the "Company" or "Anavex") (OTCBB: AVXL) today announced that the Company has arranged for the sale of up to $1,000,000 of convertible debentures in tranches. On April 20, 2011, A
Read more →AVXLFiled by newsfilecorp.com Anavex Appoints Dr. Christopher Shackleton as an Advisor HOBOKEN, NJ, April 8 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("Anavex") (OTCBB:AVXL.ob - News) today announced the appointmen
Anavex Appoints Dr. Christopher Shackleton as an Advisor HOBOKEN, NJ, April 8 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("Anavex") (OTCBB:AVXL.ob - News) today announced the appointment of Dr. Christopher Shackleton as an advisor to the Company. Dr. Shackleton is a
Read more →AVXLFiled by newsfilecorp.com ANAVEX RECEIVES APPROVAL TO COMMENCE PHASE I CLINICAL TRIAL IN ALZHEIMER S DISEASE ANAVEX 2-73 trial to be initiated immediately in Germany Hoboken, NJ
ANAVEX RECEIVES APPROVAL TO COMMENCE PHASE I CLINICAL IN ALZHEIMER S DISEASE ANAVEX 2-73 trial to be initiated immediately in Hoboken, NJ March 15, 2011 -- Anavex Life Sciences Corp. ( Anavex ) (OTCBB: AVXL) today announced that its clinical trial application (CTA) for ANAVE
Read more →AVXLFiled by newsfilecorp.com ANAVEX APPOINTS DR. JEFFREY CUMMINGS TO ITS SCIENTIFIC ADVISORY BOARD Hoboken, NJ
ANAVEX APPOINTS DR. JEFFREY CUMMINGS TO ITS Hoboken, NJ March 1, 2011 -- Anavex Life Sciences Corp. ( Anavex ) (OTCBB: AVXL) today announced the appointment of Dr. Jeffrey Cummings to the Scientific Advisory Board as a clinical expert. The Scientific Advisory Board works clos
Read more →AVXLANAVEX APPOINTS DR. RACHELLE DOODY TO SCIENTIFIC ADVISORY BOARD Hoboken, NJ - February 23 , 2011 -- Anavex Life Sciences Corp. ("Anavex", AVXL.OB) today announced the appointment of Dr. Rachelle Doody to the Scientific A
ANAVEX APPOINTS DR. RACHELLE DOODY TO SCIENTIFIC ADVISORY BOARD Hoboken, NJ - February 23, 2011 -- Anavex Life Sciences Corp. ("Anavex", AVXL.OB) today announced the appointment of Dr. Rachelle Doody to the Scientific Advisory Board (SAB) as a clinical expert. The SAB works clos
Read more →AVXLFiled by newsfilecorp.com ANAVEX ADDS DR. PAUL AISEN TO SCIENTIFIC ADVISORY BOARD Hoboken, NJ
ANAVEX ADDS DR. PAUL AISEN TO SCIENTIFIC ADVISORY Hoboken, NJ February 16, 2011 -- Anavex Life Sciences Corp. ( Anavex , AVXL.OB) today announced the appointment of Dr. Paul Aisen to the Scientific Advisory Board (SAB) as a clinical expert. The SAB works closely with the comp
Read more →AVXLFiled by newsfilecorp.com ANAVEX LIFE SCIENCES CORP. AMENDED AND RESTATED 2007 STOCK OPTION PLAN This Amended and Restated 2007 Stock Option Plan (the "Plan") provides for the grant of options to acquire common shares (t
ANAVEX LIFE SCIENCES CORP. RESTATED 2007 STOCK OPTION This Amended and Restated 2007 Stock Option Plan (the "Plan") provides for the grant of options to acquire common shares (the "Common Shares") in the capital of Anavex Life Sciences Corp., a corporation formed under the l
Read more →AVXLAnavex strengthens management team with addition of VP, Clinical Development & Medical Affairs Hoboken, NJ - February 4 , 2011 -- Anavex Life Sciences Corp. ("Anavex", AVXL.OB) today announced the addition of Dr. Angelos
Anavex strengthens management team with addition of VP, Clinical Development & Medical Affairs Hoboken, NJ - February 4, 2011 -- Anavex Life Sciences Corp. ("Anavex", AVXL.OB) today announced the addition of Dr. Angelos Stergiou to the executive management team in the role of Vi
Read more →AVXLFiled by newsfilecorp.com ANAVEX ANNOUNCES PRIVATE PLACEMENT Hoboken, New Jersey
ANAVEX ANNOUNCES PRIVATE PLACEMENT Hoboken, New Jersey, November 30, 2010 Anavex Life Sciences Corp. ( ANAVEX or the Company ) (OTCBB: AVXL) announces that it closed a Private Placement of Units On November 26, 2010 the Company issued 29,851 units at a purchase price of US$3
Read more →AVXLFiled by newsfilecorp.com INSIDER TRADING POLICY And Guidelines with Respect to Certain Transactions in Company Securities. This Insider Trading Policy (the Policy ) provides guidelines to employees, officers, and direct
INSIDER TRADING POLICY And Guidelines with Respect to Certain Transactions in Company Securities. This Insider Trading Policy (the Policy ) provides guidelines to employees, officers, and directors of ANAVEX LIFE SCIENCES CORP. (the Company ) with respect to transactions in th
Read more →AVXLFiled by newsfilecorp.com ANAVEX APPOINTS CONTRACT RESEARCH ORGANIZATIONS TO INITIATE PHASE I/IIa CLINICAL PROGRAMS, REGULATORY STRATEGIES IN ALZHEIMER S DISEASE CALIFON, NJ, BASEL, Switzerland and
ANAVEX APPOINTS CONTRACT RESEARCH ORGANIZATIONS TO INITIATE PHASE I/IIa CLINICAL PROGRAMS, REGULATORY STRATEGIES IN ALZHEIMER S DISEASE CALIFON, NJ, BASEL, Switzerland and DRESDEN, Germany August 10, 2010 --Anavex Life Sciences Corp. ( ANAVEX ) (OTCBB: AVXL) today announced th
Read more →AVXLFiled by newsfilecorp.com ANAVEX ANNOUNCES RESULTS OF ANNUAL MEETING Athens, Greece
ANAVEX ANNOUNCES RESULTS OF ANNUAL MEETING Athens, Greece, May 4, 2010 Anavex Life Sciences Corp. ( ANAVEX or the Company ) (OTCBB: AVXL) announced that it held its annual meeting of stockholders on April 28, 2010 at which its stockholders re-elected Harvey Lalach, Alison Aye
Read more →AVXLFiled by newsfilecorp.com ANAVEX PROVIDES CORPORATE UPDATES Athens, Greece
ANAVEX PROVIDES CORPORATE UPDATES Athens, Greece, April 9, 2010 Anavex Life Sciences Corp. ( ANAVEX or the Company ) (OTCBB: AVXL) announced that it has entered into various agreements, made a change of executive officer, issued shares pursuant to various agreements and close
Read more →AVXLAnavex announces a Consulting Agreement and closes a Private Placement. Athens, Greece
Anavex announces a Consulting Agreement and closes a Private Athens, Greece, November 24, 2009 Anavex Life Sciences Corp. ( ANAVEX or the Company ) (OTCBB: AVXL) announced that it has closed a US $600,000 private placement and entered into a consultant services Consultant Ser
Read more →AVXLAnavex closes 2 private placements for $290,000 (U.S.) 2009-08-11 16:31 ET - News Release An anonymous director reports: ANAVEX ANNOUNCES PRIVATE PLACEMENT Athens, Greece
Anavex closes 2 private placements for $290,000 2009-08-11 16:31 ET - News Release An anonymous director reports: ANAVEX ANNOUNCES PRIVATE PLACEMENT Athens, Greece, August 11, 2009 - Anavex Life Sciences Corp. ("ANAVEX" or the "Company") (OTCBB: AVXL) is pleased to announce
Read more →AVXLANAVEX announces convertible loan agreements and private placement Athens, Greece
ANAVEX announces convertible loan agreements and Athens, Greece, June 26, 2009 Anavex Life Sciences Corp. ( ANAVEX or the Company ) (OTCBB: AVXL) is pleased to announce that it has closed two convertible loan agreements and a private placement in which it raised an aggregate
Read more →AVXLANAVEX appoints Dr. Herv de Kergrohen as CEO to lead company through clinical trials and future growth Geneva, Switzerland
ANAVEX appoints Dr. Herv de Kergrohen as CEO to lead company through clinical trials and future growth Geneva, Switzerland June 16, 2009 Anavex Life Sciences Corp. ( ANAVEX ) (OTCBB: AVXL) today announced the immediate appointment of Herv de Kergrohen, MD, MBA, as its Chief E
Read more →AVXLSource: Anavex Life Sciences Corp. Anavex further strengthens Board of Directors Tuesday June 3, 10:58 am ET ATHENS, GREECE, June 3 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVX
Anavex further strengthens Board of Tuesday June 3, 10:58 am ET ATHENS, GREECE, June 3 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL - News) today announced the appointment of David L. Tousley, CPA, MBA, to its Board of Directors. Mr. Tousley is
Read more →AVXLAnavex Announces Appointment of Oncology Specialist to Board of Directors, Changes to Executive Management
ATHENS, Greece, May 21, 2008 (PRIME NEWSWIRE) -- Anavex Life Sciences Corp. ("ANAVEX") (OTCBB:AVXL) today announced the appointment of Alison Ayers to its Board of Directors. Ms. Ayers is currently the Worldwide Commercial Head for Oncology at Pfizer (NYSE:PFE), with responsibili
Read more →AVXLSource: Anavex Life Sciences Corp. Anavex Announces Appointment of Oncology Specialist to Board of Directors, Changes to Executive Management Wednesday May 21, 12:53 am
Anavex Announces Appointment of Oncology Specialist to Board of Directors, Changes to Executive Wednesday May 21, 12:53 am ET ATHENS, Greece, May 21, 2008 (PRIME NEWSWIRE) -- Anavex Life Sciences Corp. (``ANAVEX'') (OTC BB:AVXL.OB - News) today announced the appointment of A
Read more →AVXLDATED DECEMBER 17, 2007
ANAVEX STRENGTHENS BOARD OF DIRECTORS GENEVA, SWITZERLAND, December 17, 2007 -- Anavex Life Sciences Corp. ( ANAVEX ) (OTCBB: AVXL) today announced the appointment of Dr. Cameron Durrant to its Board of Directors. Dr. Durrant is currently Worldwide Vice President of Virology Glo
Read more →AVXLSTOCK OPTION PLAN ANAVEX LIFE SCIENCES CORP. 2007 STOCK OPTION PLAN This 2007 Stock Option Plan (the "Plan") provides for the grant of options to acquire common shares (the "Common Shares") in the capital of Anavex Life
ANAVEX LIFE SCIENCES CORP. 2007 STOCK OPTION PLAN This 2007 Stock Option Plan (the "Plan") provides for the grant of options to acquire common shares (the "Common Shares") in the capital of Anavex Life Sciences Corp., a corporation formed under the laws of the State of Nevada (
Read more →AVXLAnavex Life Sciences Corp. Announces its Preclinical Pipeline of Novel Oncology Therapies.
Anavex Life Sciences Corp. Announces its Preclinical Pipeline of Novel Oncology Therapies. KELOWNA, BRITISH COLUMBIA--Anavex Life Sciences Corp. (the "Company") (AVXL-OTCBB) announces its strategic vision for growth by discovering and developing cutting-edge drugs against solid
Read more →AVXLAnavex Life Sciences Corp. appoints VP Business Development and VP Strategic Planning. Ticker Symbol: AVXL British Columbia, Canada Anavex Life Sciences Corp. (OTCBB: AVXL) (the "Company") announces that Ms. Angela Verna
Anavex Life Sciences Corp. appoints VP Business Development and VP Strategic Planning. British Columbia, Canada Anavex Life Sciences Corp. (OTCBB: AVXL) (the "Company") announces that Ms. Angela Vernadaki and Dr. George Kalkanis have been appointed as Officers of the Company.
Read more →AVXLAnavex Life Sciences Corp. appointment of CEO and Director Ticker Symbol U:AVXL British Columbia, Canada Anavex Life Sciences Corp. (OTCBB:AVXL) (the "Company") (formerly Thrifty Printing Inc.) announces tha
Anavex Life Sciences Corp. appointment of CEO and Director Ticker Symbol U:AVXL British Columbia, Canada Anavex Life Sciences Corp. (OTCBB:AVXL) (the "Company") (formerly Thrifty Printing Inc.) announces that Dr. Panos Kontzalis, of Basel, Switzerland, has been appointed as Ch
Read more →AVXLAnavex Life Sciences Corp. Ticker Symbol: AVXL British Columbia, Canada
Anavex Life Sciences Corp. British Columbia, Canada Anavex Life Sciences Corp. acquires a portfolio of Patents and appoints Dr. Alexandre Vamvakides as CSO and Director Anavex Life Sciences Corp. (OTC BB:AVXL) (the "Company") announces that it has acquired a portfolio of three
Read more →AVXLARTICLES OF MERGER f -- Converted by S, created by BCL Technologies Inc., for SEC Filing
ARTICLES OF MERGER f -- Converted by S, created by BCL Technologies Inc., for SEC Filing
Read more →AVXLCERTIFICATE OF CHANGE DEAN HELLER Secretary of State 204 North Carson Street, Suite 1 Carson City, Nevada 89701-4299 (775) 684 5708 Website: secretaryofstate.biz Entity # C1543-2004 Document Number: 20060341596-56 Date F
DEAN HELLER Secretary of State 204 North Carson Street, Suite 1 Carson City, Nevada 89701-4299 (775) 684 5708 Website: secretaryofstate.biz Entity # C1543-2004 Document Number: 20060341596-56 Date Filed: 5/30/2006 3:30:55 PM In the office of /s/ Dean Heller Deal Heller Secretary
Read more →Competitive Position
How AVXL ranks across every disease it competes inCompetitive Position is a premium feature
See how AVXL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial